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In chronic lymphocytic leukemia (CLL), one of the best predictors of outcome is
the somatic mutation status of the immunoglobulin heavy chain variable region (IGHV)
genes. Patients whose CLL cells have unmutated IGHV genes have a median survival
of 8 years; those with mutated IGHV genes have a median survival of 25 years. To
identify new prognostic biomarkers and molecular targets for therapy in untreated CLL
patients, we reanalyzed the raw data from four published gene expression profiling
microarray studies. Of 88 candidate biomarkers associated with IGHV somatic mutation
status, we identified LDOC1 (Leucine Zipper, Down-regulated in Cancer 1), as one of
the most significantly differentially expressed genes that distinguished mutated from
unmutated CLL cases.

LDOC1 is a putative transcription factor of unknown function in B-cell
development and CLL pathophysiology. Using a highly sensitive quantitative RT-PCR
(QRT-PCR) assay, we confirmed that LDOC1 mRNA was dramatically down-regulated
in mutated compared to unmutated CLL cases. Expression of LDOC1 mRNA was also
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strongly associated with other markers of poor prognosis, including ZAP70 protein and
cytogenetic abnormalities of poor prognosis (deletions of chromosomes 6q21, 11q23,
and 17p13.1, and trisomy 12). CLL cases positive for LDOC1 mRNA had significantly
shorter overall survival than negative cases. Moreover, in a multivariate model, LDOC1
mRNA expression predicted overall survival better than IGHV mutation status or ZAP70
protein, among the best markers of prognosis in CLL. We also discovered LDOC1S, a
new LDOC1 splice variant. Using isoform-specific QRT-PCR assays that we developed,
we found that both isoforms were expressed in normal B cells (naïve > memory),
unmutated CLL cells, and in B-cell non-Hodgkin lymphomas with unmutated IGHV
genes.

To investigate pathways in which LDOC1 is involved, we knocked down LDOC1
in HeLa cells and performed global gene expression profiling. GFI1 (Growth FactorIndependent 1) emerged as a significantly up-regulated gene in both HeLa cells and
CLL cells that expressed high levels of LDOC1. GFI1 oncoprotein is implicated in
hematopoietic stem cell maintenance, lymphocyte development, and lymphomagenesis.

Our findings indicate that LDOC1 mRNA is an excellent biomarker of overall
survival in CLL, and may contribute to B-cell differentiation and malignant
transformation.

vii

TABLE OF CONTENTS

DEDICATION

iii

ACKNOWLEDGMENTS

iv

ABSTRACT

vi

TABLE OF CONTENTS

viii

LIST OF ILLUSTRATIONS

xii

LIST OF TABLES

xiv

CHAPTER 1: INTRODUCTION

1

1.1

Chronic Lymphocytic Leukemia (CLL)

1

1.2

Emergence of LDOC1 as a potential biomarker

4

1.3

LDOC1

6

1.4

Overview of Dissertation

7

CHAPTER 2: MATERIALS AND METHODS

9

2.1

Collection of patient and healthy donor samples

2.2

Cell lines

10

2.3

Nucleic acid preparation

10

2.4

Evaluation of somatic mutation status

11

2.5

Assessment of ZAP70 protein expression

11

2.6

LDOC1 mRNA expression by reverse-transcriptase
polymerase chain reaction assay

2.7

13

Expression of LDOC1 mRNA isoforms by isoform-specific
QRT-PCR assays

2.9

12

Total LDOC1 mRNA expression determined by quantitative
real-time polymerase chain reaction assays

2.8

9

14

Detection of genomic gains and losses by single

viii

nucleotide polymorphism (SNP) genotyping

15

2.10

Statistical analysis

16

2.11

LDOC1 protein knock-down in HeLa Cells

17

2. 12

Cell cycle analysis

18

2.13

Evaluation of LDOC1 protein expression knock-down
by Western blot

19

2.14

Global gene expression profiling

20

2.15

Statistical analysis of gene expression

2.16

profiling

microarray data

21

Pathway analysis

22

CHAPTER 3. LDOC1 IS DIFFERENTIALLY EXPRESSED IN CLL
PROGNOSTIC SUBTYPES AND PREDICTS OVERALL
SURVIVAL IN UNTREATED PATIENTS

23

3.1

Introduction

23

3.2

Results

23

3.2.1

LDOC1 mRNA expression is strongly associated
with known markers of poor prognosis

3.2.2

23

LDOC1 mRNA expression more strongly
predicts IGHV somatic mutation status than
does ZAP70 protein expression

3.2.3

LDOC1 mRNA expression is associated with
cytogenetic markers of prognosis

3.2.4

29

30

Total LDOC1 mRNA expression is a better
predictor of overall survival than either
IGHV somatic mutation status or ZAP70 protein
expression

30

ix

3.3

Summary

31

CHAPTER 4. LDOC1 IS DIFFERENTIALLY EXPRESSED IN NORMAL
PERIPHERAL BLOOD B CELL SUBSETS AND IN
SUBTYPES OF PRIMARY NON-HODGKIN LYMPHOMAS

33

4.1

Introduction

33

4.2

Results

33

4.2.1

RT-PCR analysis of LDOC1 mRNA reveals
a novel splice variant, LDOC1S

4.2.2

33

Total LDOC1 mRNA expression varies in NBC
and B-cell subsets, CLL and primary B-cell
lymphoma samples, and cell lines by
QRT-PCR assay

4.2.3

LDOC1 and LDOC1S mRNA isoform
expression by QRT-PCR assay

4.3

38

Summary

41
46

CHAPTER 5. GENE EXPRESSION PROFILING FOLLOWING
LDOC1 KNOCK-DOWN IN HeLa CELLS IDENTIFIES
POTENTIAL COORDINATELY-REGULATED BIOLOGIC
PATHWAYS

47

5.1

Introduction

47

5.2

Results

47

5.2.1

Optimization of LDOC1 protein knock-down

47

5.2.2

LDOC1 protein knock-down for
microarray experiment

5.2.3

51

Differentially expressed genes in siRNA
-transfected HeLa cells

x

54

5.2.4

Networks constructed from gene
expression signature

5.3

Summary

58
62

CHAPTER 6. INTERSECTION AND SUBSEQUENT VALIDATION OF
COORDINATELY DIFFERENTIALLY EXPRESSED
GENES IN HeLa CELLS AND CLL SAMPLES

63

6.1

Introduction

63

6.2

Results

64

6.3

Summary

71

CHAPTER 7. DISCUSSION

73

APPENDIX

85

BIBLIOGRAPHY

89

VITA

101

xi

LIST OF ILLUSTRATIONS

Figure 1

Histogram of the observed LDOC1 values in normalized
cycles demonstrates a clear separation of CLL samples

Figure 2

24

Expression of LDOC1 and ZAP70 mRNAs measured by
MF-QRT-PCR assay distinguishes between mutated and
unmutated cases of CLL

27

Figure 3

LDOC1 mRNA expression predicts overall survival

32

Figure 4

Structure of the LDOC1 wild-type and splice variant
mRNAs, and translated proteins

35

Figure 5

Expression of LDOC1 and LDOC1S assessed by RT-PCR

37

Figure 6

Expression of total LDOC1 mRNA measured by
QRT-PCR assay

Figure 7

39

Isoform-specific TaqMan assays are highly specific
for their target transcript

Figure 8

43

Expression of wild-type LDOC1 and LDOC1S mRNA
isoforms measured by QRT-PCR assay

Figure 9

LDOC1 protein is knocked-down by specific LDOC1
siRNAs

Figure 10

49

HeLa cells demonstrate high transfection efficiency by
siRNA

Figure 11

50

Transfection with LDOC1 siRNA has no significant effect
on cell number or cell cycle phase

Figure 12

53

Ingenuity Pathways (IPA) Core Analysis reveals
functional categories of differentially expressed genes

Figure 14

52

LDOC1 protein knock-down demonstrated by Western
blotting

Figure 13

44

59

IPA Network 2 demonstrates potential interactions
between genes that participate in cellular function and
maintenance, cancer, and gastrointestinal disease

Figure 15

61

Scatter plot comparing Affymetrix expression estimates
against QRT-PCR cycles defines the cut-off value for
LDOC1 mRNA expression on Affymetrix arrays

Figure 16

Topographic view of the QRT-PCR assays for

xii

65

the genes printed on microfluidics card

xiii

69

LIST OF TABLES

Table 1

Clinical and Laboratory Features

Table 2

Correlation of ZAP70 protein expression and
IGHV mutation status

Table 3

55

Intersection of Differentially Expressed Genes
Between CLL Samples and HeLa Cells

Table 5

29

List of Differentially Expressed Genes in
siRNA-transfected HeLa Cells

Table 4

26

67

The expression fold change values and
significance of the genes in HeLa samples that
are run on microfluidics cards

Suppl. Table 1

70

IGHV Somatic Mutation Status and Family,
Expression of LDOC1 mRNA and ZAP70 Protein,
and Genomic Abnormalities of the CLL cases

xiv

85

CHAPTER 1.

1.1

INTRODUCTION

Chronic Lymphocytic Leukemia (CLL)

Epidemiology
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the
Western hemisphere, and it accounts for one third of all leukemias in the United States.
According to the American Cancer Society 2010 estimates (American Cancer Society,
2010;http://www.cancer.org/Cancer/LeukemiaChronicLymphocyticCLL/OverviewGuide/
index), each year there are about 14,990 new cases and about 4,390 deaths due to
CLL. The lifetime risk of developing CLL for an average person is about 1 in 200. CLL
mainly affects adults of advanced age; the average age at diagnosis is 72 years. It is
uncommon in individuals younger than 40 years, and very rare in children. It is also
more common in men than women, for unknown reasons. CLL is more common in
individuals of European than Asian ancestry. There are no proven environmental risk
factors for CLL. Family history influences CLL risk, with first degree relatives of CLL
patients having a 2 to 4-fold increased risk to develop CLL.

Diagnosis
In most patients (70-80%), the disease is identified incidentally during a routine
blood test. The remaining patients present with enlarged lymph nodes or systemic
symptoms, such as malaise, night sweats and weight loss. The diagnosis is established
by evaluation of peripheral blood lymphocyte count combined with the characteristic
immunophenotype (1). In advanced stages of the disease patients show signs of
impaired function of normal bone marrow elements, such as anemia and susceptibility
to infections.
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Prognosis
The clinical course of CLL is variable and difficult to predict. Some patients live
for many years without treatment, while others have a short survival even with
treatment. As a result, a variety of clinical and laboratory parameters have been
developed to predict prognosis. Clinical staging systems developed by Binet, et al.
(1981) (2) and Rai et al. (1975) (3) remain among the most useful means to determine
prognosis. The Rai staging system, used more commonly in North America than the
Binet system, measures peripheral blood lymphocyte count, disease spread to lymph
nodes, spleen or liver, and hemoglobin levels and platelet counts. Rai stages advance
from Stage 0 (increased lymphocyte number only) to stage I (lymph node involvement),
or stage II (enlargement of spleen or liver and/or lymph nodes), stage III (anemia), and
stage IV (reduced platelet count). Physicians wait to initiate treatment until patients
reach advanced stages and develop symptomatic disease. While these staging systems
are useful to make therapeutic decisions, they are unable to predict long-term survival
with high precision, especially for patients with early stage disease. A variety of serum
markers have also been used to predict prognosis in early stage disease, and include
β2 microglobulin, lactate dehydrogenase, soluble CD23, and serum thymidine kinase.

One of the best predictors of outcome is the somatic mutation status of the
immunoglobulin heavy chain variable region (IGHV) genes. Patients whose CLL cells
have unmutated IGHV genes, about 40% of patients, have a median survival of 8 years;
patients whose CLL cells have mutated IGHV genes, about 60% of patients, have a
median survival of 25 years (4). Although the somatic mutation status is highly
associated with prognosis, it has been shown recently that the use of particular heavy
chain variable region genes, such as VH3-21, is associated with a poor prognosis,
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regardless of somatic mutation status (5, 6). Thus, the relationship between somatic
mutation status and prognosis is not absolute.

Chromosomal abnormalities, predominantly gains and deletions (del), are strong
independent predictors of prognosis in CLL. The most common abnormality is
del(13)(q14.3),

followed

by del(11)(q22.3),

trisomy 12,

del(6)(6q21-q23),

and

del(17)(p13.1). In clinical practice these abnormalities are usually assessed using a
panel of fluorescence in situ hybridization (FISH) probes (7-9). As the sole abnormality,
del(13)(q14.3) is associated with a good prognosis. In contrast, del(6)(q21-q23),
del(11)(q22.3), del(17)(p13.1), del(13)(q14.3) with other abnormalities, and trisomy 12,
are associated with more rapid disease progression and inferior survival. The
abnormalities del(17)(p13.1), the site of the TP53 gene, and del(11)(q22.3), the site of
the ATM gene, are the most important independent cytogenetic markers of poor
prognosis. Deletion of (17)(p13.1) is associated with resistance to therapy with purine
analogs, such as fludarabine, and short survival (10-12).

Gene expression profiling studies have demonstrated that the majority of
unmutated CLL cases express ZAP70 mRNA (13). Subsequently, others showed that
expression of ZAP70 protein correlates with mutation status and clinical outcome (14,
15). Recent studies suggest that ZAP70 protein expression, usually measured by flow
cytometry, may be a better predictor of time-to-treatment than somatic mutation status
(16, 17). However, standardization of ZAP70 protein measurement has remained
challenging for many clinical laboratories, which has limited its use as a routine
diagnostic test.

3

A robust biomarker of prognosis that is easily standardized between laboratories
would have a major clinical impact for CLL patients.

Treatment
Currently

the

most

effective

therapy

for

CLL

is

combination

chemoimmunotherapy with fludarabine (a purine analog that inhibits repair of DNA
damage), cyclophosphamide (a DNA damaging agent), and Rituximab (a monoclonal
antibody directed against CD20, a protein on the surface of mature B cells), i.e., FCR
(Fludarabine-Cyclophosphamide-Rituximab). These agents act synergistically to
enhance apoptosis of the CLL cells (18). The FCR regimen is the most successful
combination therapy developed to date, and provides a 6 year survival rate of 77% (18).
Despite this promising initial response, about one-half of patients treated with frontline
FCR develop relapse within 3 years of treatment, which is often resistant to further FCR
therapy. Thus, alternative specific and effective therapy options are needed to treat CLL
patients.

1.2

Emergence of LDOC1 as a potential biomarker

To identify new prognostic biomarkers and molecular targets for therapy in
untreated patients with CLL, we began this study by reanalyzing the raw data from four
published gene expression profiling microarray studies (14, 19-21). Of 88 candidate
biomarkers of IGHV somatic mutation status, we were able to confirm expression of 37
using a highly sensitive quantitative real-time polymerase chain reaction assay
performed on microfluidics cards (MF-QRT-PCR) (22). Of these candidate biomarkers,
the gene LDOC1 (Leucine zipper Down-regulated in Cancer) was one of the most
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significantly differentially expressed gene that distinguished mutated from unmutated
CLL cases. (“Mutated” or “unmutated” CLL refers to patients whose CLL cells have
somatically mutated or unmutated IGHV genes, respectively.) Since unmutated CLL is
strongly associated with poor prognosis and LDOC1 mRNA is highly upregulated in this
group of patients, we hypothesized that LDOC1 might not only serve as a promising
biomarker of prognosis, but might also contribute to CLL pathogenesis and serve as a
novel candidate molecule for targeted therapies in cancers where it is expressed
abundantly.

Schema of selection of LDOC1 as a candidate biomarker

Screening of CLL literature for microarray studies for genes
distinguishing unmutated from mutated CLL

Evaluation of 88 genes in
49 untreated CLL patients
(MF-QRT-PCR)

36 genes significant

LDOC1 most significant
high in unmutated CLL, low in mutated CLL

5

1.4

LDOC1

The LDOC1 gene, located on chromosome Xq27, encodes a 17 kDa protein
about which very little is known. A leucine zipper motif in the N-terminal region is
followed by a short proline-rich region, which contains an SH3-binding consensus
sequence, and then an acidic region in the C-terminus (23). Because leucine zipper and
SH3-binding motifs mediate protein-protein interactions, LDOC1 protein may regulate
transcription by homodimerization or heterodimerization with other transcription factors
through its leucine zipper domain. LDOC1 also may participate in cell signaling by
providing a binding surface for signaling cascade proteins within its SH3 domain.
Others have assessed LDOC1 mRNA expression in a wide range of normal tissues and
in carcinoma cell lines (23). LDOC1 mRNA is expressed ubiquitously in normal tissues,
although at relatively low levels in leukocytes, liver, and placenta compared with other
tissues. In tumor cell lines, LDOC1 mRNA is expressed in most breast cancer cell lines,
but rarely in pancreatic or gastric carcinoma cell lines. Because LDOC1 mRNA is
expressed in many normal tissues, but is not expressed in most pancreatic and gastric
carcinoma cell lines, Nagasaki and colleagues have hypothesized that LDOC1 is a
tumor suppressor gene. Ectopic LDOC1 expression is reported to inhibit NF-kB
activation in cell lines (24). Others have reported that LDOC1 induces apoptosis in
Jurkat lymphoma and K562 leukemia cell lines, but not in HeLa cervical carcinoma cells
(25). Based on these findings, it has been suggested that LDOC1 may have proapoptotic and anti-proliferative effects. The biologic functions of LDOC1 in normal Bcell development and the pathophysiology of CLL are unknown.

6

1.5

Overview of Dissertation

LDOC1 is a novel gene and a putative transcription factor. It has emerged as
one of the most significantly differentially expressed genes in CLL prognostic subtypes:
LDOC1 mRNA expression is dramatically reduced in CLL cases with somatically
mutated IGHV genes (associated with a good prognosis) compared to CLL cases with
somatically unmutated IGHV genes (associated with a poor prognosis) (22). Because
robust biomarkers of prognosis in CLL are needed, we extended our study to determine
the value of LDOC1 mRNA expression as a novel clinical biomarker of prognosis.
Because it is highly expressed in unmutated CLL cases, it also has the potential to
serve as a candidate molecule for targeted therapies.

The studies presented in this dissertation had four goals. Our first goal was to
determine if LDOC1 mRNA expression could serve as a clinically useful biomarker of
prognosis. For this, we evaluated LDOC1 mRNA expression in a large cohort of CLL
patients to assess its differential expression and correlation with overall survival. As part
of this evaluation, we also correlated LDOC1 mRNA expression with other known
prognostic parameters in CLL including IGVH somatic mutation status, cytogenetic
abnormalities, and ZAP70 expression. Our data suggest that LDOC1 mRNA expression
has prognostic significance in CLL (26). Our second goal was to investigate changes in
LDOC1 mRNA levels in normal peripheral blood B cells at different stages of
development and differentiation, as well as in primary malignant B cells from a variety of
different lymphoma subtypes. This might provide insights into the possible contributions
of LDOC1 in physiologic and pathologic changes in B cells. Our findings suggest that its
dysregulation may contribute to the pathophysiology of CLL and other B-cell
malignancies (26). It may also play a role in normal B cell development. Our third goal
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was to gain insight into the biologic pathways in which LDOC1 is involved. To achieve
this goal, we used siRNAs to reduce LDOC1 protein in HeLa cervical carcinoma cells,
which abundantly express the protein compared to other solid tumors and hematologic
malignancies that we have screened. We acquired the RNA and evaluated it for
changes in 47,000 transcripts in LDOC1-reduced cells relative to the cells containing
unaltered LDOC1 protein. We found that LDOC1 protein is involved in key signaling
pathways in HeLa cells including cellular function and maintenance, cell cycle, cellular
growth and differentiation, cell death, DNA replication and cancer. Our fourth and final
goal was to validate key genes in these pathways in CLL patient samples using a highly
sensitive QRT-PCR method. We looked for genes whose expression was concordant
with respect to LDOC1 expression in transfected HeLa cells and CLL samples,
suggesting that they might be involved in overlapping biologic pathways in the different
cell types. We identified the gene, GFI1, whose expression was decreased in HeLa
cells in which LDOC1 protein had been knocked down, and also in mutated CLL cells,
which express little or no LDOC1. GFI1 has been implicated in the development and
function of hematopoietic stem cells, normal lymphoid development and differentiation,
and lymphomagenesis.

In summary, we have shown that LDOC1 mRNA expression is a promising
novel biomarker of survival in untreated CLL patients. Correlative gene expression
profiling studies in transfected HeLa cells and CLL samples suggest that LDOC1 might
participate in a common pathway with GFI1, and contribute to CLL pathogenesis.

8

CHAPTER 2.

2.1

MATERIALS AND METHODS

Collection of patient and healthy donor samples

Peripheral blood samples were collected from 131 previously untreated CLL
patients and six healthy volunteers at The University of Texas M.D. Anderson Cancer
Center after informed consent was obtained. The study was approved by the
Institutional Review Board and conducted according to the principles expressed in the
Declaration of Helsinki. Normal CD19+ peripheral blood B cells (NBC) and CLL cells
were purified by negative selection using immunomagnetic beads, and the samples
processed as described previously (27). In addition, we enriched NBC from healthy
donors for naïve or memory B cells using a CD27 antibody column, according to the
manufacturer’s instructions (Miltenyi Biotec, Inc., Auburn, CA). In peripheral blood,
antigen-naïve B cells (CD27 ) constitute about 60% of the B cells and antigenexperienced memory B cells (CD27+) about 40% (28). We confirmed the purity of all
cell preparations by flow cytometry.

Primary lymphoma samples were obtained from either lymph node biopsy
specimens from patients with follicular lymphoma (two patients) or from the peripheral
blood of patients in leukemic phase of lymphomas (one patient with follicular lymphoma,
four patients with mantle cell lymphoma, two patients with splenic marginal zone
lymphoma, and one patient with marginal zone lymphoma). CD19+ B cells were purified
as described above (27). We ensured, by flow cytometry, that each sample contained
at least 95% CD19+ B cells.

9

2.2

Cell lines

The Epstein-Barr virus-negative Burkitt lymphoma cell line, GA-10, and the Tcell lymphoblastic lymphoma cell line, Jurkat, were maintained in RPMI medium
(Mediatech, Inc., Manassas, VA); the breast carcinoma cell line, MCF-7, and the
cervical carcinoma cell line, HeLa, were maintained in DMEM (Mediatech). Both media
were supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO) and 2 mM Lglutamine (Mediatech). We harvested the lymphoma cell lines during the exponential
phase of growth; the confluence of the MCF-7 and HeLa cells at the time of harvest is
indicated in the text.

2.3

Nucleic Acid Preparation

Total RNA was extracted using guanidine isothiocyanate/phenol-chloroform
extraction with TRIzol reagent (Life Technologies, Inc., Gaithersburg, MD) according to
the manufacturer’s instructions. The quality of the RNA was assessed by agarose gel
electrophoresis. For all subsequent PCR assays, total RNA was reverse transcribed
using random hexamers and a First-Strand cDNA synthesis kit (GE Healthcare,
Piscataway, NJ). We used a final concentration of 10 ng/µL of reverse-transcribed
product. For microarray gene expression profiling experiments, total RNA was further
purified with RNeasy MinElute Cleanup Kit (Qiagen, Valencia, CA). DNA was extracted
using a Qiagen DNeasy kit (Qiagen Sciences, Maryland) according to the
manufacturer’s instructions. The quality of the RNA used for gene expression profiling
microarray studies was assessed by Bioanalyzer analysis in the Genomics Core Facility
and met their quality control standards.
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2.4

Evaluation of the IGHV somatic mutation status

For our studies, we obtained the somatic mutation status of the IGHV genes for
a total of 130 CLL and 10 primary B-cell lymphoma samples. We assessed the somatic
mutation status of the IGHV genes in 66 CLL and 10 primary B-cell lymphoma samples
as described previously, with minor modifications (27). Patient DNA sequences were
aligned to the germline DNA sequences in VBASE II and the degree of IGHV somatic
mutation was determined (29). For 54 patients, analysis of the somatic mutation status
was performed in the clinical Molecular Diagnostics Laboratory at our institution and
obtained by review of the medical records. For 10 patients, the somatic mutation status
was performed by the Chronic Lymphocytic Leukemia Research Consortium laboratory,
and the results were obtained from the CLL Database of the Protocol Data
Management System (CLL-PDMS), which is maintained by our collaborator, Dr. Michael
Keating. The IGHV somatic mutation status was designated as “unmutated” if there
were fewer than 2%, or as “mutated” if there were 2% or more mutations compared to
the germline sequences (30).

2.5

Assessment of ZAP70 protein expression

Expression of ZAP70 protein was assessed by either immunohistochemistry or
flow cytometry. Immunohistochemical staining was performed using routinely fixed and
processed paraffin-embedded tissue sections of bone marrow core biopsy and/or clot
specimens and a specific monoclonal antibody (Upstate Cell Signaling Systems, Lake
Placid, NY), as described previously (17, 31). Immunohistochemical stains for ZAP70
protein were scored as either positive or negative by hematopathologists, and the
results obtained from the patients’ medical records. The flow cytometry assay for
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ZAP70 protein expression was performed by the Chronic Lymphocytic Leukemia
Research Consortium laboratory, as described previously (16). The results were
obtained from the CLL Database of the Protocol Data Management System (CLLPDMS), which is maintained by our collaborator, Dr. Michael Keating.

2.6

LDOC1 mRNA expression by reverse-transcriptase polymerase chain
reaction assay

We used two primer pairs to amplify either the entire coding region (primer pair
AB) or the mRNA (primer pair AC) of the LDOC1 gene in a reverse-transcriptase
polymerase chain reaction (RT-PCR) assay. Primer pair AB, designed to amplify the
entire LDOC1 coding region, yields a product of 464 bp, as reported by others (23). We
designed a second reverse primer, C (5'-AGCAGGTAACTGGAGCGCTA-3'), which
binds within the 3' untranslated region (3' UTR). Primer pair AC was expected to yield a
product of 649 bp.

The cDNA (80 ng) was amplified in the presence of primers,

reaction buffer, deoxynucleotide triphosphates (2.5

M each), and HotStar Taq DNA

polymerase. Following incubation at 95 C for 10 minutes, the cDNA was amplified for
35 cycles of at 95 C for 15 seconds, 55 C for 30 seconds, and 72 C for 45 seconds,
followed by a final extension at 72 C for 7 min. The amplified products were separated
by agarose gel electrophoresis, extracted from the gel, and purified. The sequence of
the PCR products was determined directly using the forward and reverse PCR primers,
and an ABI 3700 or 3730 DNA Analyzer (Applied Biosystems, Foster City, CA). The
sequences were aligned to the LDOC1 reference sequence (GenBank RefSeq
NM_012317) using NCBI SPLIGN algorithm and LaserGene v7.2 software (DNASTAR).
The cDNA amount and integrity were ensured by amplifying the housekeeping gene,
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beta-actin, using forward (5'-GATCATGTTTGAGACCTTCAAC-3') and reverse (5'TCTTTGCGGATGTCCACGTC-3') primers (27). The RT-PCR conditions were identical
to those used for the LDOC1 RT-PCR assay; and the reactions were run
simultaneously with the reactions amplifying LDOC1.

2.7

Total LDOC1 mRNA expression determined by quantitative real-time
polymerase chain reaction assays

We used two different quantitative real-time polymerase chain reaction assays
(QRT-PCR) to detect total LDOC1 mRNA expression: 1) a high-throughput assay using
microfluidics cards (MF-QRT-PCR) and 2) a standard QRT-PCR assay. The LDOC1
TaqMan probe and primer sets were identical in both assays. The primers and probe
bind to 3' UTR sequences that are present both in wild-type LDOC1 and its splice
variant, LDOC1S (TaqMan Assay, Hs00273392_s1, Applied Biosystems). In the MFQRT-PCR assay, custom microfluidics cards were printed with primers and probes
corresponding to 88 candidate mRNA biomarkers of IGHV somatic mutation status,
including LDOC1 and ZAP70. We used five endogenous control genes (18S rRNA,
GAPD, PGK1, GUSB, and ECE-1), and performed the MF-QRT-PCR assays, as
described previously (22). The expression of each gene was assessed in duplicate.

In the standard QRT-PCR assay, the PCR reactions for LDOC1 mRNA were
carried out in 25 L reaction volumes that contained 5 L cDNA at a concentration of
10ng/ L. In addition, 1X TaqMan Universal PCR Master Mix without AmpErase UNG,
unlabeled LDOC1-specific PCR primers, and a 6-carboxy fluorescein (FAM)–labeled
TaqMan minor groove binder (MGB) probe were added. In all experiments, we amplified
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of 18S ribosomal RNA (rRNA) as an internal control to normalize the LDOC1 values.
The probe for 18S rRNA is labeled with the VIC reporter dye. The PCR reaction
conditions were as follows. After incubation at 95°C for 10 minutes, the cDNA was
amplified for 45 cycles of denaturation at 95°C for 15 seconds and combined
annealing/extension at 60°C for 1 minute. Each sample was analyzed in triplicate in a
PRISM 7000 Sequence Detector (Applied Biosystems). We used the 7500 Fast System
version 1.4.0 software (Applied Biosystems) to analyze the fluorescence emission data
following QRT-PCR. The threshold cycle (Ct) values of each sample were exported to
Microsoft Excel for further analysis. The Ct value represents the cycle number at which
fluorescence originating from each sample passes a predetermined single threshold.
The ΔCt for LDOC1 mRNA was obtained by subtracting the Ct value of 18S rRNA from
the Ct value of LDOC1 mRNA for each sample. The LDOC1 mRNA expression levels in
test samples are presented as relative quantities (RQ), computed as: 2-ΔΔCt = 2-(ΔCt test ΔCt calibrator)

, where the calibrator represents an equal mixture of cDNA obtained from GA-

10 and Jurkat cells.

2.8

Expression of LDOC1 mRNA isoforms by isoform-specific QRT-PCR
assays

In order to assess the contribution of each of the LDOC1 mRNA isoforms to the
total LDOC1 mRNA expression, we designed two specific TaqMan assays that
distinguish between the isoforms.We used Primer Express software (Applied
Biosystems) to search for and select the primer and probe combinations from a ranked
list generated by the software. In the TaqMan assay that specifically recognizes the
wild-type LDOC1 sequences (Custom LDwt1, part number 4331348), the 5’ primer
anneals to sequences 5'–TGGTGCCCTACATCGAGATG-3', the 3' primer anneals to
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sequences 5’-CGAGGAAGGCCCGGTAA-3', and the TaqMan probe anneals to
sequences 5'–ATAGCCCCATCCTAGGTG-3'. In the TaqMan Assay that specifically
detects the splice variant LDOC1S transcript, the TaqMan probe (Custom LDsv1, part
number 4331348) targets the junction sequence located between nucleotides 183 to
233

and

718

to

785.

The

TTCCAAGCACTTCCGAGTGA-3',

the

5'

primer
3’

primer

anneals
anneals

to
to

sequences

5'-

sequences

5'-

ATGGAACAGCTGCGGCTG-3', and the TaqMan probe anneals to sequences 5'CTATTCCTGGCGCAGCAG-3'. Assays were ordered on the Applied Biosystems
Custom TaqMan Assay Design Tool (https://www5.appliedbiosystems.com/tools/cadt/).

2.9

Detection of genomic gains and losses by single nucleotide polymorphism
(SNP) genotyping

Genomic DNA was extracted from purified CLL cells, as described above.
Genotypic analysis was performed on DNA obtained from 100 CLL samples using the
Illumina HumanHap610 chip, according to the manufacturer’s instructions, in
collaboration with Dr. Bogdan Czerniak, Department of Anatomic Pathology.
Background subtraction and normalization were performed using the default settings in
the Illumina BeadStudio software. Log R ratios (LRR), B allele frequencies (BAF), and
genotype calls were exported from BeadStudio for analysis in the R statistical
programming environment (version 2.8.1). Segments of constant copy number in the
LRR data were identified by applying the circular binary segmentation (CBS) algorithm,
as implemented in the DNAcopy package (version 1.16.0) (32). Segments with mean
LRR < 0 .15 and two bands in the BAF plot were called “deleted”; segments with mean
LRR > 0.15 and four bands in the BAF plot were called “gained”. The data were
evaluated to detect common abnormalities associated with CLL, i.e., deletions of 6q21,
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11q22.3, 13q14.3, and 17p13.1, and trisomy 12; we also evaluated the DNA for gains or
deletions of LDOC1. The data were analyzed by our collaborator, Dr. Kevin Coombes,
Department of Bioinformatics and Computational Biology. Following analysis, the
genomic changes were visually inspected to ensure the accuracy of the calls made by
the computer algorithm were correct.

2.10

Statistical analysis

Comparisons of LDOC1 positive and negative patient groups were performed
using two different tests (Table 1). For discrete variables (all parameters except age),
we used the two-sided Fisher’s exact test to compare the means of the two groups. For
the continuous variable (age), we used an unpaired two-sample t-test assuming
unequal variances to compare the mean. Time-to-event (survival) analysis was
performed using Cox proportional hazards models. Significance was assessed using
the log-rank (score) test. To assess multivariate models, we used a forward-backward
stepwise algorithm to eliminate redundant factors and optimize the Akaike Information
Criterion (AIC) (33). All computations were performed using either the survival package
(version 2.35-8) in the R statistical programming environment (version 2.11.1)
(performed by Dr. Kevin Coombes) or STATA Statistics/Data Analysis software version
10.0 (performed by Hatice Duzkale). Multivariate survival analysis and analysis of the
88 candidate biomarkers of prognosis by MF-QRT-PCR were performed in collaboration
with Dr. Kevin Coombes.
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2.11

LDOC1 protein knock-down in HeLa cells

HeLa cells were obtained from ATCC, and were at passage 2 since their receipt
from the ATCC at the beginning of the experiments. The cells were thawed and
passaged twice before seeding for the experiment. When they reached approximately
90% confluence they were harvested by trypsinization and counted; the cell viability,
assessed by trypan blue dye exclusion, was greater than 90%. The cells were seeded
at 1.5 x 105 cells per well in 2 mL complete DMEM medium (Mediatech), into 6-well
plates.

Twenty four hours after seeding, the cultures were inspected using an inverted
light microscope to ensure that the cells had reached 40-50% confluence and were
evenly distributed. For transfection, the complete medium containing 10% FBS was
replaced with DMEM medium containing 1% FBS, according to the manufacturer’s
instructions (Lipofectamine 2000, Invitrogen, Carlsbad, CA). Knock-down of LDOC1 and
LDOC1S mRNAs was performed using siRNA pools that contain four different siRNAs,
all of which hybridize to the amino acid coding region (ON-TARGETplus SMARTpool
siRNA pool; Thermo Scientific, Lafayette, CO). One of these siRNAs also recognizes
the splice variant LDOC1S. For the negative controls, we used either a single nontargeting siRNA (ON-TARGETplus Non-targeting siRNA #1 for the time-course
optimization experiments) or a pool of four non-targeting siRNAs (ON-TARGETplus
Non-targeting Pool for the global gene expression profiling microarray experiments).
The non-targeting siRNAs do not hybridize to any region in the human genome, and
control for sequence-nonspecific silencing effects during siRNA transfection experiment.
Water was used for the “mock” transfection control. The siRNAs were added to each
culture at a final concentration of 100 nM. The cells were incubated with the siRNAs in
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the presence of 1% FBS for 24 hours at 37 C with 5% CO2. After this incubation, FBS
was added to achieve a final concentration of 10% FBS. For the optimization
experiments, the cells were continuously incubated with the siRNAs until they were
harvested. For the gene expression profiling studies, the cells were incubated with the
siRNAs for 56 hours, the medium replaced with complete medium containing 10% FBS,
and then harvested at 93 hours post-transfection.

In the same experiment we also assessed the transfection efficiency using
fluorescent-labeled control siRNAs (siGLO Transfection indicator-Red; Thermo
Scientific). The transfection efficiency was determined using fluorescence microscopy
by counting three different fields at 40x magnification, and calculated as: Efficiency =
mean number of the red-fluorescing cells / (mean number of the total fluorescent + nonfluorescent cells).

2. 12

Cell cycle analysis

After harvesting, cells were washed with cold PBS and fixed with cold ethanol
(70%). They were incubated at 4oC at least for 24 hours, and stained with propidium
iodide (PI). A flow cytometer was used to measure DNA content of the cells. Cell cycle
analysis was done using software MultiCycle (Phoenix Flow Systems, Inc., San Diego,
CA).
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2. 13

Evaluation of LDOC1 protein expression K\knock-down by Western blot

Whole cell lysates were prepared from freshly isolated cultured HeLa cells.
After removing the medium, the cells were washed, detached with trypsin, transferred to
cold 15 mL culture tubes, and spun at 1500 rpm for 5 minutes at 4oC in a refrigerated
centrifuge. After removing the supernatant, the cell pellets were stored at -80oC for a
minimum of 24 hours to denature the cellular proteins. The pelleted cells were lysed on
ice in lysis buffer (25 mM Hepes, pH 7.7, 400 mM sodium chloride, 1.5 mM magnesium
chloride, 2 mm ethylenedinitrilotetraacetic acid (EDTA), 0.5% Triton X-100).
Immediately before use, the reducing agent 3 mM dithiothreitol (DTT), 20 mM betaglycerophosphate, 2 mm sodium orthovanadate (Na3VO3), 5 mM sodium fluoride, 25
mM para-nitrophenyl-phosphate disodium (PNPP), 0.1 mM phenyl methyl sulfonyl
fluoride (PMSF), and complete protease inhibitor cocktail (Roche, Indianapolis, IN) were
added to the lysis buffer. The lysates were homogenized by sonication, placed on ice
for 30 minutes, and spun at 4oC in a refrigerated centrifuge to remove cellular debris.
The protein concentration was measured by Bradford assay. Total protein (100 µg) was
heat denatured for 3 minutes in sample buffer (50 mM Tris-HCl (pH 6.8), 10% glycerol,
2% SDS, 0.025% bromophenol blue, 2.5% ß-mercaptoethanol), separated by 15% TrisHCl SDS polyacrylamide gel electrophoresis, and transferred to a polyvinylidene
fluoride (PVDF) membrane. The membrane was blocked with 3% non-fat milk in PBS-T
buffer (PBS with 0.05% Tween 20) and incubated overnight at 4OC with either affinitypurified polyclonal mouse anti-human LDOC1 antibody (dilution 1:500; Abnova, Taiwan)
or monoclonal mouse anti-human beta-actin antibody conjugated to horse-radishperoxidase (HRP) (dilution 1:25,000; Sigma, St. Louis Missouri). All antibodies were
diluted in 3% milk with PBS-T. The membranes were washed twice with PBS-T for 10
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min, once with PBS for 10 min, and then once with ddH2O for 30 min. To detect LDOC1,
the membranes were incubated for a minimum of 60 minutes at room temperature with
anti-mouse secondary antibody conjugated to HRP (GE Healthcare, United Kingdom)
and washed, as described above. After exposure to chemiluminescent substrate for 1
minute, the peroxidase reaction was detected using the Enhanced Chemiluminescentplus (ECL-plus, GE Healthcare) system for LDOC1 and the ECL system (GE
Healthcare) for beta-actin.

2.14

Global gene expression profiling

We used GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa
Clara, CA) for the 3’ in vitro transcription (IVT) expression analysis. This chip contains
more than 54,000 probe sets that interrogate 47,000 transcripts from approximately
38,500 well-characterized human genes. The hybridizations were performed in triplicate
according to the manufacturer’s instructions. The experiment was performed using six
chips, three chips for each of two conditions: LDOC1 siRNA-treated HeLa cells (LD
group) and non-targeting siRNA-treated HeLa cells (NT group). Briefly, total RNA (100
ng per chip) was reverse transcribed using a T7 oligo(dT) primer to synthesize cDNA
that contains the T7 promoter sequence. This first strand cDNA was then converted to
double-stranded DNA by DNA polymerase in the presence of RNase H, which
simultaneously degrades the RNA during the reaction. The in vitro transcription reaction
was performed in the presence of T7 RNA polymerase and biotinylated ribonucleotide
analogues. Subsequently, the amplified RNA (cRNA) was purified to remove
unincorporated nucleotide triphosphates (NTP), enzymes, salts and inorganic
phosphate to improve the stability of the biotin-modified cRNA. The expected size of the
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cRNA is between 250-5500 nucleotides (nt), with a peak size of 600-1200 nt. The cRNA
was then fragmented to obtain 35-200 nt fragments, with a peak size ranging from 100120 nt. The fragments were then hybridized to the chips at 45oC for 16 hours. The chips
were then scanned with a GeneArray Scanner (Hewlett-Packard, Palo Alto, CA). The
entire hybridization procedure was performed in the institutional Core Facility.

2.15

Statistical analysis of gene expression profiling microarray data

All data pre-processing and statistical analyses were performed in R, a free
software environment for statistical computing and graphics (http://www.r-project.org/).
As part of standard quality control (QC) analysis, the .CEL files were quantified using
the MAS5 algorithm. The data quality was examined by preparing RNA degradation
plots, Bland-Altman (M-versus-A) pairwise plots, density plots, and box plots. Then, the
expression levels were quantified using the method “Robust Multiarray Analysis (RMA)”.
A two-sample t-test was performed to identify differentially expressed genes between
LD and NT groups. To account for multiple testing, a beta-uniform mixture (BUM) model
was applied to estimate false discovery rate (FDR).

In order to identify genes that were coordinately expressed in HeLa and CLL
cells, we compared the data obtained from the HeLa knock-down experiments with
gene expression profiling data previously acquired on 30 CLL samples in our laboratory
(34). These CLL samples had been hybridized to the Affymetrix U133A 2.0 gene
expression microarrays, which contain 22,283 probe sets. The array assesses the
expression level of 18,400 transcripts and variants, including 14,500 well-characterized
human genes. Data were processed using RMA, and two group comparisons between
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LDOC1-high and LDOC1-low samples were performed using two-sample t-tests. The
microarray gene expression analyses were performed in collaboration with Dr. Kevin
Coombes.

2.16

Pathway analysis

Pathway analysis of differentially expressed genes was performed using the
Ingenuity Pathway Analysis (IPA), a web-based algorithm (Ingenuity® Systems, IPA
version 9.0, www.ingenuity.com) (35). For this analysis, the mean gene expression
values were first base-two log transformed. To determine fold changes, the ratio of the
LD/NT groups were calculated using Excel. Based on their p values, the ratios of the
most significantly differentially expressed 107 genes were uploaded into the IPA
algorithm. A core analysis was performed using a 0.5 fold change in ratio as the cut-off,
querying only the direct interactions. The IPA algorithm uses literature-curated and
database-originated a priori knowledge (Ingenuity Knowledge Base) and builds
networks using those interactions as scaffolds, filling in with the gene list uploaded by
the user.
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CHAPTER 3. LDOC1 IS DIFFERENTIALLY EXPRESSED IN CLL PROGNOSTIC
SUBTYPES AND PREDICTS OVERALL SURVIVAL IN UNTREATED PATIENTS

3.1

Introduction

In an earlier study performed to identify candidate biomarkers associated with IGHV
somatic mutation status in 49 previously untreated CLL patients, our group identified
LDOC1 as one of the genes that was differentially expressed with strong statistical
significance between mutated and unmutated cases (22). We have expanded this
analysis to a total of 131 samples obtained from previously untreated CLL patients and
evaluated the potential of LDOC1 mRNA as biomarker of prognosis. Our analyses
included correlations with known standard clinical and laboratory markers of prognosis,
and univariate and multivariate survival analyses.

3.2

Results

3.2.1

LDOC1 mRNA expression is strongly associated with known markers of
poor prognosis

We expanded our previous analysis of 49 samples (22) to a total of 131 samples
obtained from untreated CLL patients. We found that the distribution of LDOC1
expression was bimodal, with no patients exhibiting CT values between 7 and 8 cycles
Figure 1). Thus, we defined samples to be LDOC1-positive if
negative if CT > 7.5.
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CT

7.5 and LDOC1-

Figure 1. Histogram of the observed LDOC1 values in normalized cycles
demonstrates a clear separation of CLL samples. Normalized Ct values of 131 CLL
samples obtained by MF-QRT-PCR assay are shown on the X-axis. The red vertical
line indicates the cut-off point to allocate LDOC1 mRNA expression into positive (to the
left of the red line) or negative (to the right of the red line) groups. The figure contains
continuous (blue line) and discrete (histogram) approximations of the "probability
density" function. The area of each bar represents the percentage of patient samples
that have values in the interval represented by the x-axis values.
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The patient characteristics in both groups are summarized in Table 1. With
respect to age, gender, Rai stage, white blood cell count, or serum beta-2 microglobulin
levels at the time the sample was obtained, there were no statistically significant
differences between patients whose cells expressed LDOC1 mRNA and those whose
cells were negative for LDOC1 mRNA. Since we originally identified LDOC1 mRNA as a
biomarker of IGHV somatic mutation status (22), its expression strongly correlated with
the somatic mutation status, as expected (Fisher’s exact test; p=2.20 x 10-16). For each
case, the data for the IGHV somatic mutation status, IGHV family, percent homology
with the germline sequence, and LDOC1 mRNA expression, as well as ZAP70 protein
expression and cytogenetic findings, are listed in Supplementary Table 1.

Out of a total of 131 cases, 65 out of 67 mutated cases (97%) were negative for
LDOC1 mRNA, and 43 out of 63 unmutated cases (68%) were positive for LDOC1
mRNA; the IGHV somatic mutation status was unavailable for one case (Figure 2A,
Supplementary Table 1). Equivalently, 43 out of 45 (96%) LDOC1-positive cases were
unmutated and 65 out of 85 (76%) LDOC1-negative cases were mutated. Thus, 22
cases (17%) showed discordance between LDOC1 mRNA expression and IGHV
somatic mutation status; two mutated cases were LDOC1-positive and 20 unmutated
cases were LDOC1-negative.
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Table 1. Clinical and Laboratory Features†, **
All
Patients
(n = 131)

LDOC1
positive
(n = 46)

LDOC1
negative
(n = 85)

Age in years
Median
(range)

59
(27 – 82)

60
(27 – 82)

59
(27 – 81)

0.6796

Gender
Male, n (%)
Female, n (%)

81 (62%)
50 (38%)

27 (59%)
19 (41%)

54 (64%)
31 (36%)

0.7066

Rai stage
0-2, n (%)
3-4, n (%)

(n = 131)
102 (78%)
29 (22%)

(n = 46)
35 (76%)
11 (24%)

(n = 85)
67 (79%)
18 (21%)

0.826

WBC count
150x109/L, n (%)
> 150x109/L, n (%)

(n = 131)
118 (90%)

(n = 46)
38 (83%)

(n = 85)
80 (94%)

13 (10%)

8 (17%)

5 (6%)

Serum 2 microglobulin
< 4, n (%)
4, n (%)
IGHV somatic mutation
status
Mutated, n (%)
Unmutated, n (%)

(n = 130)
98 (75%)
32 (25%)

(n = 46)
31 (67%)
15 (33%)

(n = 84)
67 (80%)
17 (20%)

0.1384

(n = 130)
67 (52%)
63 (48%)

(n = 45)
2 (4%)
43 (96%)

(n = 85)
65 (76%)
20 (24%)

2.20 x 10-16

(n = 113)
51 (45%)
62 (55%)

(n = 39)
30 (77%)
9 (23%)

(n = 74)
21 (28%)
53 (72%)

1.06 x 10-6

ZAP70 protein status
Positive, n (%)
Negative, n (%)

p value*

0.0621

Cytogenetic changes
(n = 100)
(n = 39)
(n = 61)
None, n (%)
27 (27%)
14 (36%)
14 (23%)
isolated del(13q), n (%)
36 (36%)
5 (13%)
30 (49%)
0.0005834
del(6q), del(11q), del(17p),
+12, or
37 (37%)
20 (51%)
17 (28%)
del(13q) with other
abnormalities, n (%)
†
Age, Rai stage, WBC count, and serum 2 microglobulin values are reported for the
time the sample was obtained for LDOC1 mRNA expression; IGHV somatic mutation
status, ZAP70 protein status, and cytogenetic changes were determined on samples
obtained before treatment.
* All p values were calculated using the two sided Fisher’s exact test except for age in
years, which was calculated using the two-sided t-test.
** For serum 2 microglobulin and IGHV somatic mutation status, one value was
unavailable; for ZAP70 protein, 18 values were unavailable, for genomic abnormalities,
31 values were unavailable.
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Poor prognosis

Figure 2: Expression of LDOC1 and ZAP70 mRNAs measured by MF-QRT-PCR
assay distinguishes between mutated and unmutated cases of CLL. (A) Dot-plot
for LDOC1 mRNA expression. For the mutated cases, 65 out of 67 mutated cases
were unambiguously negative for LDOC1 mRNA (higher
positive (lower

CT values) and 2 were

CT values). For the unmutated cases, 43 out of 63 unmutated cases

were positive for LDOC1 mRNA and 20 were negative. (B) Dot-plot for ZAP70 mRNA
expression. For the unmutated cases, 53 out of 63 unmutated cases were positive for
ZAP70 mRNA and 10 were negative. Eleven out of 67 mutated cases were positive for
ZAP70 mRNA and 56 were negative. The

CT value considered for threshold = 5.3
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3.2.2

LDOC1 mRNA expression more strongly predicts IGHV somatic mutation
status than does ZAP70 protein expression

Since evaluation of ZAP70 protein expression has been considered a surrogate
biomarker for IGHV somatic mutation status (36, 37), we evaluated the association
between IGHV somatic mutation status and ZAP70 protein expression, measured by
immunohistochemistry or flow cytometry (IHC/Flow). We detected a positive association
between ZAP70 protein positivity by IHC/Flow and IGHV somatic mutation status
(Fisher’s exact test; p=1.42 x 10-9). Of the 112 cases for which ZAP70 protein
expression data were available, 24 (21%) showed discordance between IGHV somatic
mutation status and ZAP70 protein expression (Table 2), consistent with the results of
previous studies (14, 16, 17, 31, 36, 37). Eleven out of 59 mutated cases (19%) were
ZAP70 positive; 13 out of 53 unmutated cases (25%) were ZAP70 negative. Thus,
LDOC1 mRNA expression was more strongly associated with IGHV somatic mutation
status than was ZAP70 protein expression.

ZAP70 protein

UM

M

Total

Positive

40

11

51

Negative

13

48

61

Total

53

59

112

Table 2. Correlation of ZAP70 protein expression and IGHV mutation status. Only
in 112 patients data were available for both ZAP70 protein expression and IGHV
mutation status. UM, IGHV-unmutated; M, IGHV-mutated
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3.2.3

LDOC1 mRNA expression is associated with cytogenetic markers of
prognosis

We found that expression of LDOC1 mRNA correlated with cytogenetic markers
of prognosis (Table 1, Fisher’s exact test; p= 0.0005834; Supplementary Table 1).
Cases that were negative for LDOC1 mRNA were more likely to harbor isolated
deletions in chromosome 13q14.3, a marker of good prognosis, compared to samples
that were positive for LDOC1 mRNA. In contrast, cases that were positive for LDOC1
mRNA were more likely to harbor genomic abnormalities associated with poor
prognosis, i.e., del(6)(q21), del(11)(q22.3), del(17)(p13.1), +12, or with del(13)(q14.3),
another cytogenetic marker of poor prognosis, than cases that were negative for
LDOC1 mRNA expression.

3.2.4

Total LDOC1 mRNA expression is a better predictor of overall survival
than either IGHV somatic mutation status or ZAP70 protein expression

Since LDOC1 mRNA expression was associated with IGHV somatic mutation
status and ZAP70 protein expression, both strong predictors of prognosis in CLL
patients, we sought to determine if LDOC1 mRNA expression could also serve as a
biomarker of prognosis. Thus, we analyzed the relationship between LDOC1 mRNA
expression and overall survival. We found that patients whose cells were negative for
LDOC1 mRNA had a significantly longer median survival than patients whose cells
were positive, regardless of whether overall survival was measured from the time of
diagnosis (Figure 3; logrank test, p = 0.009581) or from the time the sample was
obtained (logrank test, p = 0.02294; data not shown). The median survival for the
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LDOC1 mRNA negative patients was not reached, whereas the median survival for
LDOC1 mRNA positive patients was 164 months.

Further, we applied the Akaike Information Criterion (AIC) to a multivariate
model that incorporated LDOC1 mRNA expression, ZAP70 protein expression, and
IGHV somatic mutation status. The optimal model retained only LDOC1 mRNA
expression (AIC = 167.93), eliminating ZAP70 protein expression (AIC = 169.2) and
mutation status (AIC=171.02). Smaller values of AIC provide better models (33). Thus,
in this sample set LDOC1 mRNA expression was a better predictor of overall survival
than either IGHV somatic mutation status or ZAP70 protein expression. (The
multivariate model was constructed by our collaborator, Dr. Kevin Coombes).

3.3

Summary

We have shown that LDOC1 mRNA expression positively correlates with
important known biomarkers of poor prognosis, i.e., unmutated IGHV somatic mutation
status, ZAP70 protein expression, and cytogenetic markers of poor prognosis. Further,
LDOC1 mRNA expression is associated with shorter overall survival in a univariate
analysis. Finally, LDOC1 mRNA is an excellent biomarker of prognosis in untreated CLL
patients, and is a better predictor of overall survival than either IGHV somatic mutation
status or ZAP70 protein expression, the current gold standard biomarkers of prognosis
in CLL.
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not reached

13.7 years

Figure 3.

LDOC1 mRNA expression predicts overall survival. Overall survival

was measured from the time of CLL diagnosis. The median survival for LDOC1 mRNA
positive patients was 164 months (13.7 years); the median survival for the LDOC1
mRNA negative patients was not reached.
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CHAPTER 4. LDOC1 IS DIFFERENTIALLY EXPRESSED IN NORMAL PERIPHERAL
BLOOD B CELL SUBSETS AND IN SUBTYPES OF PRIMARY NON-HODGKIN
LYMPHOMAS

4.1 Introduction

Little is known about the expression of LDOC1 mRNA in normal B cells (NBC) or
in lymphoid malignancies other than CLL. To begin to understand its biological role in B
cell development, differentiation, activation, and transformation we screened a variety of
normal and malignant B-cell subsets for LDOC1 mRNA expression. We used the RTPCR to identify novel mRNA variants and the QRT-PCR to measure the relative
amounts of the isoforms. During the course of our studies we discovered a new splice
variant, LDOC1S.

4.2 Results

4.2.1

RT-PCR analysis of LDOC1 mRNA reveals a novel splice variant, LDOC1S

We assessed LDOC1 mRNA expression in NBC, a variety of primary B-cell
lymphoma samples, and carcinoma cell lines, using two primer pairs, AB and AC
(Figure 4). Primer pair AB was designed to amplify the entire LDOC1 coding region and
yield a product of 464 bp (23). The reverse primer, C, in primer pair AC was designed to
bind within the 3' UTR and yield a product of 649 bp. Using primer pair AB we detected
strong expression of the expected wild-type 464 bp product in seven unmutated CLL
cases (CLL 42, 46, 49, 51, 53, 54, 60), two NBC samples (NBC 4, 6), and the MCF-7
breast carcinoma cell line, which has been shown to express high levels of LDOC1 (23)
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(Figure 5A and B). We detected faint or no RT-PCR products in seven mutated CLL
cases (CLL 58, 62, 12, 37, 61, 67, 99), or in the GA-10 Burkitt lymphoma and Jurkat Tcell lymphoblastic lymphoma cell lines. However, primer pair AC yielded two distinct
bands in all positive samples, the expected 649 bp product and an unexpected 165 bp
product. Three out of four additional NBC samples, as well as normal peripheral blood T
cells and HeLa cervical carcinoma cells were also positive with both primer pairs (data
not shown).

In a subset of CLL cases that expressed LDOC1 mRNA (CLL 46, 49, 53), we
determined the sequence of the 464, 165, and 649 bp products. We also determined
the sequence of the 464 and 649 base pair products in a subset of NBC cases (NBC 1,
3, 5). The sequences from the 464 and 649 bp products were identical to the published
LDOC1 reference sequence (GenBank RefSeq NM_012317). Sequence analysis of the
165 bp product revealed that it was a splice variant (Figure 4B). The LDOC1 gene is an
intronless gene that encodes an mRNA of 1376 bp (23). The LDOC1 and LDOC1S
mRNAs have identical translation start sites, with a sequence similar to that described
by Kozak (38). The splice variant contains canonical splice donor (AG|GTACGT at
nucleotide 232) and acceptor sequences (TGTCTTTGTTCCAG|G at nucleotide 704), as
well as a branch sequence (TTCAT at nucleotide 685) (Alex’s Splice Site Finder,
version 0.5; NNSplice, version 0.9). Thus, in the splice variant, approximately the first
third of the amino acid coding region is joined with the 3' UTR at nucleotide 718. After
one codon (GAA, glutamic acid), the coding sequence is terminated by a stop codon
(TAG), followed by a 3’UTR that is identical to the wild-type sequence. If translated, the
165 bp splice variant would produce a truncated protein of 44 amino acids that contains
the leucine zipper region of the wild-type protein; the proline rich-region (amino acids
46-65) and the remainder of the coding region would be absent (Figure 4C).
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Figure 4:

Structure of the LDOC1 wild-type and splice variant mRNAs, and

translated proteins.

(A and B) Structure of the LDOC1 and LDOC1S mRNAs,

respectively. The LDOC1 gene is an intronless gene that spans 1376 bp. Open boxes
represent 5’ and 3’ untranslated regions (UTR) and shaded boxes represent the coding
sequences (CDS); the number of nucleotides is indicated below. (C) Alignment of the
amino acid sequences of wild-type LDOC1 protein and the putative splice variant
protein. The wild-type mRNA encodes a protein composed of 146 amino acids. The
splice variant mRNA, if translated, would yield a truncated protein of 44 amino acids
that corresponds mainly to leucine zipper region of the wild-type LDOC1 protein.
Identical residues are indicated by asterisks; the dashes indicate nucleotides that have
been removed from the LDOC1S mRNA by alternative splicing. The leucine zipper
domain (amino acids 5-40) in the wild-type protein, indicated by an open blue box,
would be preserved in the splice variant.
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Figure 5:

Expression of LDOC1 and LDOC1S assessed by RT-PCR. (A)

Expression of LDOC1 and LDOC1S in cell lines, normal peripheral blood B cells,
and CLL cells. Wild type LDOC1 (464 and 649 bp) and LDOC1S (165 bp) were
detected in the MCF7 breast cancer cell line, two normal peripheral blood B cell (NBC)
samples, and two unmutated CLL samples. Little or no LDOC1 or LDOC1S were
detected in the Burkitt lymphoma cell line, GA10, the T-cell lymphoblastic lymphoma
cell line, Jurkat, or two mutated CLL samples. (B) Expression of LDOC1 and LDOC1S
in CLL cells. Wild type LDOC1 (464 and 649 bp) and LDOC1S (165 bp) were detected
in the five additional unmutated CLL samples. Little or no LDOC1 or LDOC1S were
detected in five additional mutated CLL samples. The amount of cDNA amplified for
each sample was comparable, as shown by the beta-actin signal.
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4.2.2

Total LDOC1 mRNA expression varies in NBC and B-cell subsets, CLL and
primary B-cell lymphoma samples, and cell lines by QRT-PCR assay

We assessed the expression of LDOC1 mRNA in unfractionated NBC samples
and in NBC samples that had been enriched for naïve (CD27 ) or memory (CD27+) B
cells. We also assessed its expression in 10 primary B-cell non-Hodgkin’s lymphoma
samples, for which we had determined the IGHV somatic mutation status. The primary
lymphoma samples included three follicular lymphoma samples (FL1, FL2, FL3, all
mutated), four mantle cell lymphoma samples (MCL1, MCL2, and MCL4, mutated;
MCL3 unmutated), one extranodal marginal zone B-cell lymphoma sample (MZL,
unmutated), and two splenic marginal zone lymphoma samples (SMZL1, unmutated;
SMZL2, mutated). For these experiments we used the commercially available QRTPCR assay that detects total LDOC1 mRNA; it does not distinguish between the
isoforms. The results for unfractionated NBC and CLL samples, and lymphoma and
carcinoma cell lines were consistent with the results obtained by the RT-PCR assay
(Figure 6). For the fractionated NBC samples, the fraction enriched for naïve B cells
expressed higher levels of LDOC1 mRNA than the fraction enriched for memory B cells.
We found that LDOC1 mRNA was also expressed in primary B-cell lymphoma samples.
Although the sample size is insufficiently large for a statistical analysis of individual
lymphoma subtypes, there was a trend for the unmutated lymphoma samples,
regardless of subtype, to express higher levels of LDOC1 mRNA than mutated
samples.
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Figure 6
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Figure 6: Expression of total LDOC1 mRNA measured by QRT-PCR assay.
LDOC1 levels are measured using a commercially-available TaqMan assay that does
not distinguish between the LDOC1 and LDOC1S mRNA isoforms; mRNA quantity
shown on the y-axis refers to total LDOC1 mRNA. LDOC1 expression was measured in
carcinoma (HeLa, MCF7) and lymphoma (GA10, Jurkat) cell lines, unfractionated
normal peripheral blood B cells (NBC4, NBC6), normal peripheral blood B cells
enriched for memory B cells (NBC9M, NBC10M, NBC11M, NBC13M), normal
peripheral blood B cells enriched for naïve B cells (NBC9N, NBC10N, NBC11N,
NBC13N), and unmutated (U) or mutated (M) CLL and primary B-cell lymphoma
samples, including follicular (FL), mantle cell (MCL), marginal zone (MZL), or splenic
marginal zone (SMZL) lymphoma samples. Error bars represent the standard error of
the ΔΔCt values.
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4.2.3

LDOC1 and LDOC1S mRNA isoform expression by QRT-PCR assay

Because the commercially available QRT-PCR assay fails to distinguish
between the LDOC1 and LDOC1S mRNA isoforms, we were unable to assess the
contribution of each isoform to the total LDOC1 mRNA levels that we observed using
the RT-PCR and commercially available QRT-PCR assays. Thus, we designed QRTPCR assays that distinguish between the isoforms. (The primer and TaqMan probe
components of each assay are described in Chapter 2.)

In order to determine the assay specificity, that is, whether the TaqMan assay
designed against the sequences of either LDOC1 or LDOC1S mRNA recognize their
own sequence specifically, and discriminate efficiently between the two, we prepared
synthetic templates that consist of the amplicons between the forward and reverse
primer sequences, inclusive: the wild-type template is 5'-TGGTGCCCTACATCGAGAT
GATAGCCCCATCCTAGGTGTTACCGGGCCTTCCTCG-3', and the splice variant
template is 5'-TTCCAAGCACTTCCGAGTGACTATTCCTGGCGCAGCAGCAGCCGCA
GCTGTTCCAT-3'. We used 33,000 molecules of each primer as the cDNA template.
Unlike cDNA obtained from samples, the primer templates allowed us to calculate more
precisely the amount of input template in PCR reactions. We determined that the assay
for the wild-type LDOC1 mRNA isoform recognizes the wild-type template with 14 x 106
fold specificity compared to the splice variant template, as determined by RQ of 2-ΔCt =
2-(Ct target - Ct homolog). The assay for LDOC1S mRNA isoform recognizes the splice variant
template with 43 x 103 fold specificity compared to the wild-type template (Figure 7).
Since a specificity of more than 30 x 103 fold is the standard used for the commercially
available TaqMan assays (Dr. John Pfeifer, Life Sciences, personal communication),
the assays we designed are highly specific. To account for the different assay
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efficiencies, we used the data from all samples to fit a model expressing total LDOC1
mRNA as a weighted linear combination of wild-type (WT) and splice variant (SV)
contributions. For normalized mRNA levels, we found the optimal model to be Total =
(0.67 x WT) + (0.24 x SV) (developed by Dr. Kevin R. Coombes).

We re-assessed the previously-tested samples described above using the
isoform-specific TaqMan assays (Figure 8). In general, for both benign and malignant
cells, cells that expressed the wild-type LDOC1 mRNA also expressed the splice variant
LDOC1S

mRNA,

but

the

wild-type
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isoform

was

predominant.

Taq-LDOC1S
/LDOC1S

14.5 cycles

Taq-LDOC1S
/LDOC1

24 cycles
Taq-LDOC1
/LDOC1

Taq-LDOC1
/LDOC1S

Water/Taq-LDOC1

Figure 7: Isoform-specific TaqMan assays are highly specific for their target
transcript. Synthetic templates consist of the amplicons between the forward and
reverse primer sequences were synthesized for LDOC1 and LDOC1S, corresponding to
the sequences uniquely found in each isoform. TaqMan assays designed to specifically
recognize their own templates were tested for specificity against each other’s template.
Each arrow marks the threshold set for calculating the ΔCt values for the corresponding
TaqMan assay against two different templates. The underlines indicate the templates,
LDOC1 or LDOC1S. The specificities of the TaqMan assays are calculated as follows:
ΔCt TaqLD1sv (Ct target LD1svTemplate-Ct homolog LD1wtTemplate)= 2-(11.012-26.415) = 43,327
ΔCt TaqLD1wt (Ct target LD1wtTemplate-Ct homolog LD1svTemplate)= 2-(10.358-34.104) = 14,068,839
TaqLD1: TaqMan assay for corresponding LDOC1 isoform (sv or wt); LD1wt: wild type
LDOC1; LD1sv: splice variant of LDOC1
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Figure 8
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Figure 8: Expression of wild-type LDOC1 and LDOC1S mRNA isoforms measured
by QRT-PCR assay. We designed an assay that distinguishes between the isoforms.
Gene expression was measured in carcinoma (HeLa, MCF7) and lymphoma (GA10,
Jurkat) cell lines, unfractionated normal peripheral blood B cells (NBC4, NBC6), normal
peripheral blood B cells enriched for memory B cells (NBC9M, NBC10M, NBC11M,
NBC13M), normal peripheral blood B cells enriched for naïve B cells (NBC9N,
NBC10N, NBC11N, NBC13N), and unmutated (U) or mutated (M) CLL and primary Bcell lymphoma samples, including follicular lymphoma (FL), mantle cell lymphoma
(MCL), marginal zone lymphoma (MZL), or splenic marginal zone lymphoma (SMZL)
samples. Error bars represent the standard error of the ΔΔCt values.
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3.3 Summary

We evaluated LDOC1 mRNA expression in subsets of normal and malignant B
cells, and in solid tumor cell lines. We discovered a shorter form of LDOC1, a novel
splice variant that we called LDOC1S. If translated into protein, the splice variant would
consist almost entirely of the leucine zipper region of the wild type protein, raising the
possibility that it might interfere with the function of the wild type protein through
dimerization between leucine zipper regions. The LDOC1S mRNA is co-expressed with
wild type LDOC1 although its amount might vary between the cell types. However, we
have not screened a sufficiently large number of samples to derive a statistically
meaningful conclusion about the biological significance of LDOC1/LDOC1S ratio.

During our initial screen of 131 CLL samples for differential LDOC1 mRNA
expression and subsequent survival analyses we used an MF-QRT-PCR assay. This
assay uses an inventoried TaqMan assay that recognizes both LDOC1 and LDOC1S
mRNAs.

After we discovered LDOC1S, we developed and tested isoform-specific

TaqMan assays to determine the contribution of LDOC1S to the total LDOC1 mRNA
measured by the MF-QRT-PCR assay. We found that the contribution of LDOC1S was
very small. Had the expression of LDOC1S been significantly higher than that of wild
type LDOC1 we would have screened a larger cohort of CLL patients to measure
LDOC1S mRNA to evaluate its value as a biomarker of overall survival by itself.
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CHAPTER 5. GENE EXPRESSION PROFILING FOLLOWING LDOC1 KNOCKDOWN IN HeLa CELLS IDENTIFIES POTENTIAL COORDINATELY-REGULATED
BIOLOGIC PATHWAYS

5.1

Introduction

LDOC1 is a novel gene of unknown function. We hypothesized that global gene
expression profiling would illuminate the biologic processes in which LDOC1 is involved.
We chose HeLa cervical carcinoma cells, which highly express endogenous LDOC1
protein, in order to elucidate changes in the transcriptome induced by LDOC1 protein
knock-down.

5.2

5.2.1

Results

Optimization of LDOC1 protein knock-down

There are no previously published studies that demonstrate expression of
endogenous LDOC1 protein using Western blot analysis. In order to demonstrate
LDOC1 protein expression, we screened polyclonal and monoclonal LDOC1 antibodies
from six commercial sources. Despite numerous experiments to optimize the conditions
of the assay, we identified only one polyclonal antibody that gave reproducible results
(although with some background) in a Western blot assay, which we used for our
studies.

Before performing gene expression profiling, we first performed experiments to
optimize HeLa cell transfection. As described in Materials and Methods, we transfected
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HeLa cells with a siRNA pool that contains siRNAs directed against four different
regions of the LDOC1 mRNA, including sequences within the LDOC1S mRNA. The
transfected cells were harvested every 24 hours following transfection for 4 days, and
LDOC1 protein expression assessed by Western blot analysis using a polyclonal
antibody to LDOC1. The results of a representative experiment are shown in Figure 9.
The cell confluence at 24 (data not shown), 48 (data not shown), 72, and 96 hours was
60%, 95%, 100%, and >100%, respectively. In untransfected cells (lanes 1, 5, and 9)
LDOC1 protein was not observed until the cells reached 100% confluence, 72 hours
after initiating the cultures, and was maximally expressed when the cells reached
>100% confluence, 96 hours after initiating the cultures. By 72 hours after transfection,
LDOC1 protein expression was substantially reduced in cells transfected with LDOC1
siRNA, compared to untransfected cells, cells transfected with non-targeting siRNAs, or
mock transfected cells. Western blot analysis performed using an antibody to beta-actin
demonstrates that equivalent amounts of protein were added to each well.

In the same experiment, we also assessed the transfection efficiency by
fluorescence microscopy 24 hours after transfection with fluorescently-labeled siRNA,
siGLO Red. The efficiency was calculated by dividing the number of fluorescent cells by
the total number of cells (mean of three different fields counted at 40X magnification),
and was 92% (Figure 10).
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72 hours

UnTfx

LD1siR

Mock

96 hours

NTsiR

UnTfx

LD1siR

Mock

NTsiR

Figure 9. LDOC1 protein is knocked-down by specific LDOC1 siRNAs. Cells were
harvested at 72 or 96 hours after transfection and protein lysates (50 µg) were loaded
into each well. Western blot analysis was performed using a polyclonal antibody to
LDOC1 (upper panel) or a monoclonal antibody to beta actin (lower panel). The LDOC1
protein is 17 kD (band is shown by arrow on upper panel). Abbreviations: UnTfx,
untransfected; LD1siR, LDOC1 siRNA pool; Mock, mock transfection (all transfection
reagents other than siRNAs); NTsiR, non-targeting siRNA #1.
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Figure 10. HeLa cells demonstrate high transfection efficiency by siRNA.
HeLa cells transfected by fluorescently labeled siRNA, siGLO Red, were visualized 24
hours after transfection under inverted light microscope (left) or fluorescent microscope
(right) (20X magnification).
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5.2.2. LDOC1 protein knock-down for microarray experiment

The results of our optimization experiments indicated that LDOC1 protein was
maximally knocked down 96 hours after transfection. Thus we chose to harvest cells at
approximately this time point for subsequent gene expression profiling. Knock-down
experiments were conducted in triplicate for each condition (untransfected, LDOC1
siRNA transfected, non-targeting siRNA transfected, and mock transfected). At 93
hours after transfection the cells had reached > 100% confluence. They were harvested
and evaluated for cell number and viability (trypan blue exclusion), and cell cycle
(propidium iodide staining followed by flow cytometry). In addition, protein and RNA
were extracted to perform Western blot analysis (to confirm knock-down) and gene
expression profiling. With respect to cell number, viability (data not shown), or cell cycle
phase we found no difference between HeLa cells transfected with LDOC1 siRNAs and
non-targeting siRNAs (Figure 11 A and B). We confirmed the high efficiency of LDOC1
protein expression knock-down by Western blot analysis (Figure 12).
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Figure 11.

Transfection with LDOC1 siRNA has no significant effect on cell

number or cell cycle phase. (A) The cell number was evaluated by trypan blue
exclusion and (B) cell cycle phases were evaluated by propidium iodide staining.

Untransfected

LDOC1
siRNAs

Non-Targeting
siRNAs

Mock

LDOC1

Beta-actin

Figure 12. LDOC1 protein knock-down demonstrated by Western blot analysis.
Protein was obtained 93 hours after transfection with siRNAs and 100 µg protein lysate
was loaded into each well. LDOC1 protein was efficiently knocked down by specific
LDOC1 siRNAs, but was unaffected by non-targeting siRNAs (upper panel). Antibody to
beta-actin demonstrates that equivalent amounts of protein (100 µg per lane) were
added to each well (lower panel).
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5.2.3

Differentially expressed genes in siRNA-transfected HeLa cells

We compared the gene expression profiles on RNA obtained from HeLa cells
treated with LDOC1 siRNAs (LD) or non-targeting (NT) siRNAs. The array quality
control analysis indicated that there was no significant evidence of outliers or abnormal
hybridization patterns, and the overall array quality was good. The percentage of genes
present for all the arrays ranged between 47-50% (expected between 30-60%), and the
average, minimum, and maximum backgrounds were similar across the arrays.

In order to identify differentially expressed genes between the LD and NT
groups, we performed two-sample t-tests. Using false discovery rates (FDR) of 0.05,
0.1, and 0.2, we identified 1, 4, and 107 differentially expressed genes, respectively.
The fold value changes and p values of the 107 differentially expressed genes are
presented in Table 3. In this table, fold changes indicate the ratio LD / NT. A positive
fold change value indicates an increase in gene expression in LD compared to NT cells;
a negative value indicates a decrease in gene expression in LD compared to NT cells.
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Table 3. List of Differentially Expressed Genes in siRNA-transfected HeLa Cells
Probe ID
204454_at
1556551_s_at
214352_s_at
205809_s_at
223266_at
211949_s_at
221539_at
210537_s_at
212113_at
211212_s_at
209169_at
212010_s_at
226264_at
202132_at
211503_s_at
226020_s_at
219529_at
221059_s_at
207940_x_at
228801_at
1561403_at
243349_at
1558378_a_at
212775_at
227639_at
223592_s_at
202412_s_at
205315_s_at
209920_at
243145_at
226897_s_at
212808_at
206383_s_at
220144_s_at
217457_s_at
204078_at
215071_s_at
224404_s_at
241715_x_at

Gene Symbol
LDOC1
SLC39A6
KRAS
WASL
STRADB
NOLC1
EIF4EBP1
TADA2L
LOC552889
ORC5L
GPM6B
CDV3
SUSD1
WWTR1
RAB14
DAB1 /// OMA1
CLIC3
COTL1
CNR1
ORMDL1
SOHLH1
KIAA1324
AHNAK2
OBSL1
PIGK
RNF135
USP1
SNTB2
BMPR2
--ZC3H7A
NFATC2IP
G3BP2
ANKRD5
RAP1GDS1
SC65
HIST1H2AC
FCRL5
ACPT
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Fold Change
-5.24
1.39
1.35
1.28
1.07
1.27
-1.48
1.22
1.23
1.12
1.17
-1.27
1.43
1.20
1.20
1.11
1.09
-1.04
-1.10
1.18
-1.24
-1.19
1.43
-1.07
1.09
1.13
1.16
1.20
1.39
1.13
1.22
1.19
1.13
-1.06
-1.07
1.09
1.14
-1.16
-1.19

P value
0.000000144
0.0000154
0.0000199
0.0000209
0.0000385
0.0000494
0.0000536
0.0000723
0.0000877
0.000088
0.0000883
0.0000927
0.0000968
0.000100038
0.000109765
0.000139154
0.000139573
0.000141816
0.000156992
0.000172399
0.000207897
0.000210587
0.000216582
0.000224804
0.000238186
0.000242704
0.000252094
0.000259242
0.000261638
0.000273762
0.000276911
0.000278652
0.00028099
0.000288035
0.00029406
0.000300573
0.000302292
0.000305902
0.000307205

Probe ID
1570130_at
232503_at
221734_at
234724_x_at
1568640_at
236053_at
218576_s_at
235266_at
212906_at
203491_s_at
237837_at
56256_at
1552307_a_at
218751_s_at
212451_at
232349_x_at
221520_s_at
224471_s_at
221396_at
226297_at
219066_at
205226_at
230155_x_at
1557896_at
208018_s_at
223692_at
239055_at
1556127_at
237740_at
224190_x_at
211587_x_at
241273_at
208378_x_at
228936_at
208297_s_at
201959_s_at
211801_x_at
1562783_at
201562_s_at

Gene Symbol
SPATS2
--PRRC1
PCDHB18
ASPRV1
LOC100128653
DUSP12
ATAD2
GRAMD1B
CEP57
--SIDT2
TTC39C
FBXW7
SECISBP2L
DCAF6
CDCA8
BTRC
TAS2R7
--PPCDC
PDGFRL
MSL1
--HCK
NMNAT1
FLJ43663
DIP2A
--NOD1
CHRNA3
--FGF5
--EVI5
MYCBP2
MFN1
LOC100128840
SORD

Fold Change
1.22
-1.16
1.09
-1.16
-1.17
-1.12
-1.08
1.34
-1.10
1.20
-1.10
1.13
1.15
1.14
1.34
1.18
-1.09
1.04
-1.15
1.15
1.14
-1.39
-1.29
-1.22
-1.14
1.29
-1.22
-1.15
-1.13
1.14
-1.12
1.13
-1.24
-1.03
1.28
1.12
1.15
-1.28
1.21
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P value
0.000310473
0.00031898
0.000320222
0.000322211
0.000324145
0.000336741
0.00034521
0.000351744
0.000361663
0.000364253
0.000367065
0.000369489
0.000370903
0.000383996
0.000385468
0.000386059
0.00040314
0.000404038
0.000412271
0.000412343
0.000426938
0.000431297
0.000436594
0.00045447
0.000459992
0.000462599
0.00046488
0.00046601
0.000477778
0.000492446
0.000511636
0.000514578
0.000515624
0.000522271
0.000527051
0.00052857
0.000529138
0.000533645
0.000534678

Probe ID
229274_at
214869_x_at
227780_s_at
222975_s_at
211993_at
1555057_at
1569846_at
239788_at
226413_at
202658_at
200598_s_at
229795_at
203056_s_at
233261_at
217988_at
200841_s_at
219658_at
200975_at
222142_at
1554372_at
209254_at
1558747_at
1568957_x_at
220653_at
1568931_at
212520_s_at
229909_at
201479_at
226568_at
233827_s_at
1556336_at
235201_at
239009_at
1570165_at
212220_at
235059_at
217753_s_at
1553542_at
213286_at
208209_s_at

Gene Symbol
GNAS
GAPVD1
ECSCR
CSDE1
WNK1
NDUFS4
----LOC400027
PEX11B
HSP90B1
--PRDM2
EBF1
CCNB1IP1
EPRS
PTCD2
PPT1
CYLD
--KLHDC10
SMCHD1
SRGAP2P1
ZIM2
--SMARCA4
B4GALNT3
DKC1
FAM102B
SUPT16H
LOC100131735 /// LOC100291994 ///
RBMX /// RBMXL1
--KIAA0754
--PSME4
RAB12
RPS26
CCDC125
ZFR
C4BPB
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Fold Change
1.35
1.09
-1.31
1.13
1.38
1.17
-1.20
1.36
1.10
-1.23
1.29
1.16
1.40
1.32
1.11
1.44
1.20
1.09
1.08
-1.19
1.25
1.46
1.11
-1.25
-1.17
1.16
1.08
-1.06
-1.06
1.36

P value
0.00053949
0.000546859
0.00054713
0.000548207
0.000549098
0.000562023
0.000573165
0.000587081
0.000592997
0.000599795
0.00061511
0.000629294
0.000646625
0.000655267
0.00065986
0.00066462
0.000665816
0.000671499
0.000681179
0.000691453
0.000700331
0.000718725
0.000721806
0.000734443
0.000743993
0.000753233
0.000758928
0.000761875
0.000762703
0.000766658

1.19
1.09
-1.26
-1.06
1.23
1.28
-1.06
1.26
1.31
-1.12

0.000766725
0.000784229
0.000787619
0.000789026
0.000801126
0.000809335
0.000814191
0.000814995
0.000822981
0.000837838

Probe ID
202197_at
227087_at
236806_at

5.2.4

Gene Symbol
MTMR3
INPP4A
---

Fold Change
1.14
1.14
1.12

P value
0.000855254
0.000856684
0.000868555

Networks constructed from gene expression signature

The differentially expressed genes listed in Table 3 belong to a variety of
functional categories, including enzymes (BMPR2, BTRC, GNAS, KRAS, and RAB14),
kinases (HCK, PDGFRL, and STRADB), and transcriptional regulators (FBXW7,
PRDM2, and SMARCA4). To better understand the potential function of these genes
and their relationships, we performed a network analysis using Ingenuity Pathways. A
Core Analysis was performed using a 0.5 fold change value as the cut-off, querying only
direct interactions between the 107 most significantly expressed genes. As shown in
Figure 13, LDOC1 protein knock-down induced alterations in expression of a variety of
genes that participate in wide range of biological processes, including regulation of
gene expression, cellular function and maintenance, cancer, cell cycle, cellular growth
and proliferation, cellular assembly and organization, cell death, and DNA replication,
recombination and repair. To illustrate the construction of networks, Network # 2 is
shown in Figure 14.
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Figure 13. Ingenuity Pathways (IPA) Core Analysis reveals functional categories of differentially expressed genes. Of 16
networks, only the most significant 6 networks are shown from the IPA analysis. Genes in bold-face type are focus molecules that
we identified as differentially expressed (Table 3) and were uploaded into the Core Analysis by the investigator. Genes in nonbold-face type are identified by the Ingenuity Knowledge Base as potential interaction partners and incorporated into networks.
Red arrows indicate up-regulated molecules and green arrows indicate down-regulated molecules.
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Figure 14. IPA Network 2 demonstrates potential interactions between genes that
participate in cellular function and maintenance, cancer, and gastrointestinal
disease. The shapes of gene symbols indicate their functional group. Solid lines
indicate the direct interactions. Numerical values under the genes indicate mRNA fold
changes in LDOC1 knocked-down cells compared to the NT control cells. Red indicates
up-regulation and green indicates down-regulation of the mRNA of the respective gene.
Genes are placed according to their location in the cell, i.e., extracellular space, plasma
membrane, cytoplasm, or nucleus; genes for which the location is unknown are located
on the right (“unknown”).
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Figure 14
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5.3

Summary

We have successfully knocked-down LDOC1 protein in HeLa cells and
performed gene expression profiling microarray analysis. This analysis revealed 107
genes that are significantly differentially expressed between the cells transfected with
LDOC1 siRNAs and non-targeting control siRNAs. These genes belong to a wide
variety of functional groups. The list of differentially expressed genes were subjected to
further analysis by performing a Core Analysis in Ingenuity Pathways, which allowed us
to assign the differentially expressed genes into potential networks and visualize
interactions between the differentially expressed genes within functional categories. The
IPA analysis also revealed other potential interaction partners extracted from the
Ingenuity Knowledge Base, in addition to the 107 genes identified by gene expression
profiling experiment. Upon inspection of the networks, LDOC1 was found only in
network 3. Relatively little is known about the function of LDOC1, and none of the
molecules indicated as interaction partners of LDOC1 in this network have been shown
experimentally to interact with LDOC1 in a mammalian system. Ingenuity Pathways
constructs networks using all available published information, including bioinformatic
analyses as well as experimental data, from the literature and databases. Thus, the
results require validation in different tissue types and cellular contexts.
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CHAPTER 6. INTERSECTION AND SUBSEQUENT VALIDATION OF
COORDINATELY DIFFERENTIALLY EXPRESSED GENES IN HeLa CELLS AND
CLL SAMPLES

6.1

Introduction

Although gene expression profiling using microarrays allows the expression of a
large number of genes to be assessed in a single experiment, the dynamic range of
microarrays is relatively small (39, 40). Thus, genes identified as differentially
expressed using microarrays should be validated using a more sensitive method, such
as a QRT-PCR assay. We chose to validate genes that we identified as “coordinately
regulated” in LDOC1 knock-down experiments in HeLa cells and in CLL samples. We
approached this problem in two ways.

First, we compared two lists of differentially expressed genes generated by
gene expression profiling microarray studies using Affymetrix arrays: (1) the list of
genes differentially expressed between HeLa cells transfected with LDOC1 siRNAs (to
knock-down LDOC1 expression) and non-targeting siRNAs, and (2) the list of genes
differentially expressed with respect to LDOC1 mRNA expression in 30 CLL samples,
obtained from a previous gene expression profiling microarray (34). Genes that were
concordant for LDOC1 expression in both groups (HeLa and CLL) and whose function
suggests that they might have relevance to the pathophysiology of CLL were to be
evaluated by QRT-PCR assay.

Second, we compared the two lists of differentially expressed genes generated
by a MF-QRT-PCR assay for 43 candidate biomarkers of prognosis and 5 endogenous
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control genes; 23 potential biomarkers have been reported previously (22) and 20 have
been identified subsequently (Abruzzo LV, et al., manuscript submitted). We had
previously assessed 76 CLL samples for expression of these 48 genes (including
LDOC1). We performed the same MF-QRT-PCR assay on RNA obtained from
transfected HeLa cells, as described above.

6.2

Results

In the gene expression profiling experiments of HeLa cells using Affymetrix
microarrays, the groups with “high” and “low” LDOC1 expression corresponded to cells
that had been transfected with non-targeting siRNAs or LDOC1 SiRNAs, respectively.
For the CLL samples, we reanalyzed the Affymetrix microarray raw data to allocate
samples into groups with “high” and “low” LDOC1 mRNA expression. To achieve this,
we first plotted LDOC1 mRNA expression levels for each sample to determine if there
was a clear separation between samples with respect to LDOC1 mRNA expression
(data not shown). Since this analysis failed to separate the samples into two distinct
groups, we then plotted the Affymetrix expression data against the MF-QRT-PCR assay
data collected previously in our laboratory (Figure 15). Based on this analysis, we
concluded that the expression value of 7.6 on the log2 scale defined the best cut-off to
separate the groups with LDOC1-high from LDOC1-low expression for Affymetrix data
(shown as the black vertical line in the figure). Differentially expressed genes between
the LDOC1-high and LDOC1-low groups were determined using two sample t-tests.
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Figure 15. Scatter plot comparing Affymetrix expression estimates against QRTPCR cycles defines the cut-off value for LDOC1 mRNA expression on Affymetrix
arrays. Vertical lines indicate plausible cut-offs to separate LDOC1 mRNA expression
into groups with high (right of the line) or low expression (left of the line), based on gene
expression profiling Affymetrix data. The horizontal line separates LDOC1 mRNA
expression into groups with high (below the line) or low expression (above the line)
based on the MF-QRT-PCR data. The expression value of 7.6 on the log2 scale defined
the best cut-off to separate the groups with LDOC1-high from LDOC1-low expression
for Affymetrix data (shown as the black vertical line in the figure). PCR cycles = Mean
ΔCt value based on the MF-QRT-PCR assay. The colored vertical lines indicate
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alternative cutoff values to set the threshold for LDOC1 mRNA positivity measured by
Affymetrix microarrays.

Next we compared the list of differentially expressed genes in CLL groups and
HeLa cell groups with “high” and “low” LDOC1 expression. To narrow down the number
of genes for validation, we selected concordantly expressed genes for which the p value
in CLL and HeLa cells was < 0.05. The overlapping, differentially expressed genes are
listed in Table 4.

Table 4. Intersection of Differentially Expressed Genes Between CLL Samples
and HeLa Cells. The CLL and HeLa p values refer to the significance of differential
expression for that gene between LDOC1-high and LDOC1-low samples. The p
combined value refers to the significance of gene expression change in the CLL and
HeLa data when they are assessed simultaneously (Fisher’s exact test). For CLL cells
the fold change values indicate the gene expression ratios of cases with high LDOC1 /
low LDOC1; for HeLa cells the fold change values indicate the gene expression ratios of
NT (high LDOC1) / LD (low LDOC1) cells. A positive value indicates an increase in
gene expression; a negative value indicates a decrease in gene expression. Genes that
are concordant show the same direction of change in CLL and HeLa samples.
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AffyProbeID
204454_at
217753_s_at
219024_at
201676_x_at
216222_s_at
208794_s_at
202944_at
48659_at
214452_at
205780_at
202678_at
200881_s_at
202600_s_at
205882_x_at
207031_at
213017_at
201524_x_at
214474_at
205469_s_at
200834_s_at
219411_at
216037_x_at
214136_at
213475_s_at
221579_s_at
204476_s_at
202350_s_at
212288_at
205280_at
216576_x_at
217835_x_at
200629_at
201798_s_at
201969_at
203767_s_at
204520_x_at
212744_at
201460_at
217418_x_at
203988_s_at
219128_at
212162_at
202669_s_at
200002_at
218571_s_at
218145_at
41858_at
78383_at
214949_at
205149_s_at
207149_at
216401_x_at
212350_at
210087_s_at
216699_s_at

CLL P value
7.17E-11
0.041280928
0.011023732
0.045090524
0.019039041
0.007330058
0.041408589
0.039342604
3.93E-06
0.025449019
0.005916584
0.038323819
0.019171443
0.031204126
0.044814279
0.028034783
0.041995482
0.040485963
0.00720127
0.001163252
0.027896294
0.035630998
0.003592161
0.02024539
0.001444114
0.028243382
0.001019723
0.037095652
0.038571401
0.02880998
0.041520332
0.048204048
0.006273149
0.002178054
0.019546553
0.008232359
0.049204322
0.017569059
0.040932625
0.001676991
0.014004784
0.027990074
0.025205352
0.047204876
0.023344055
0.006111609
0.017332907
0.039295836
0.034035352
0.011042873
0.030557123
0.030799181
0.026389523
0.014594328
0.030924111

CLL Fold Change
1.653
1.692
0.745
1.095
0.881
1.278
0.875
1.088
1.246
1.404
1.192
1.173
0.649
0.600
0.926
1.148
1.149
0.900
1.260
0.891
1.107
0.851
0.899
1.260
1.166
0.887
0.924
0.817
0.949
2.351
1.118
1.376
0.902
0.831
0.954
1.212
0.930
1.240
0.707
0.706
0.843
0.874
0.909
0.918
1.136
1.261
0.930
0.933
1.280
1.138
0.930
2.376
1.256
0.897
1.268

HeLa P value
1.44E-07
0.000814191
0.003040962
0.003547553
0.003716954
0.003920538
0.004546794
0.004699016
0.005504185
0.00559713
0.005796159
0.005981868
0.00651801
0.007339724
0.007569084
0.007682522
0.010959026
0.011108058
0.013697712
0.013924734
0.014487817
0.015468312
0.01557867
0.016225922
0.017597489
0.019006562
0.019681207
0.020512879
0.02161636
0.022686296
0.023418633
0.023496573
0.023795307
0.024250526
0.024951662
0.025267505
0.025816847
0.026763556
0.030087019
0.031232095
0.032302933
0.035029663
0.035307156
0.036583127
0.04066558
0.04164203
0.041647164
0.042754313
0.044100829
0.044118806
0.04499689
0.045939624
0.047558577
0.048712568
0.049976695
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HeLa Fold Change
5.253
1.059
0.736
1.065
0.548
1.039
0.883
1.062
1.285
1.294
1.080
1.043
0.803
0.960
0.878
1.112
1.066
0.799
1.193
0.984
1.241
0.966
0.835
1.177
1.075
0.920
0.871
0.850
0.863
1.191
1.034
1.151
0.930
0.942
0.924
1.070
0.843
1.090
0.936
0.944
0.959
0.888
0.829
0.994
1.035
1.148
0.975
0.950
1.089
1.160
0.843
1.066
1.052
0.967
1.105

P Combined
4.44E-16
0.000379822
0.000378917
0.001558113
0.000747027
0.000329257
0.001803235
0.001773999
4.04E-07
0.001403986
0.000386849
0.002150508
0.001248037
0.002148678
0.003049066
0.002033838
0.003996535
0.003915664
0.001008507
0.000194872
0.003562117
0.004686716
0.000603868
0.002963391
0.000294286
0.004578915
0.000237146
0.006225207
0.00674485
0.005446398
0.007716366
0.0088155
0.001464315
0.000573014
0.004206952
0.001971513
0.009741301
0.004073119
0.009482234
0.000568649
0.003936273
0.007772744
0.007141121
0.012712462
0.007556221
0.002360794
0.00594361
0.01241388
0.011259854
0.004202982
0.010435128
0.010697648
0.0096395
0.005864396
0.011548508

Concordant
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Of the 51 statistically significantly differentially expressed genes between CLL
and HeLa groups we performed a review of the literature to identify genes whose
reported function suggested that they might contribute to the pathogenesis of CLL. We
selected six for validation by QRT-PCR assay: NRIP1 (Hs00942766_s1, Applied
Biosystems),

DNAJA1

(Hs00266011_m1,

Applied

Biosystems),

UBE2N

(Hs00854751_s1, Applied Biosystems), ITGAL (Hs00158218_m1, Applied Biosystems),
MAPKAPK2 (Hs00358962_m1, Applied Biosystems), and CLCN4 (Hs00156541_m1,
Applied Biosystems). None of these genes were significantly differentially expressed
between HeLa groups. Therefore, we did not proceed with validation in CLL samples.

For the second approach, we assessed the HeLa groups (LD and NT) for the
expression of 43 genes previously identified as potential biomarkers of prognosis in CLL
(22). The format of the MF-QRT-PCR assay (microfluidics card) is presented in Figure
16. The cDNA prepared from the same RNA used for the gene expression profiling
microarray experiments was assessed. The microfluidics card contained eight ports;
each port contains TaqMan assays that recognize the 48 different genes. The card was
loaded with cDNA from triplicate cultures (three LD and three NT cultures, one sample
from each culture in duplicate). The analysis identified three differentially expressed
genes with a p value of less than 0.05: LDOC1, GFI1, and FOXO1 (Table 4).
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SLAMF1
BCL7A
SLAMF1
BCL7A
SLAMF1
BCL7A
SLAMF1
BCL7A
SLAMF1
BCL7A
SLAMF1
BCL7A
SLAMF1
BCL7A
SLAMF1
BCL7A

OAS3
LASS6
OAS3
LASS6
OAS3
LASS6
OAS3
LASS6
OAS3
LASS6
OAS3
LASS6
OAS3
LASS6
OAS3
LASS6

AICDA
NRIP1
AICDA
NRIP1
AICDA
NRIP1
AICDA
NRIP1
AICDA
NRIP1
AICDA
NRIP1
AICDA
NRIP1
AICDA
NRIP1

NT5C2
CD14
NT5C2
CD14
NT5C2
CD14
NT5C2
CD14
NT5C2
CD14
NT5C2
CD14
NT5C2
CD14
NT5C2
CD14

FGL2
NUDC
FGL2
NUDC
FGL2
NUDC
FGL2
NUDC
FGL2
NUDC
FGL2
NUDC
FGL2
NUDC
FGL2
NUDC

TPST2
MLXIP
TPST2
MLXIP
TPST2
MLXIP
TPST2
MLXIP
TPST2
MLXIP
TPST2
MLXIP
TPST2
MLXIP
TPST2
MLXIP

RIOK2
EGR3
RIOK2
EGR3
RIOK2
EGR3
RIOK2
EGR3
RIOK2
EGR3
RIOK2
EGR3
RIOK2
EGR3
RIOK2
EGR3

SKI
FLNB
SKI
FLNB
SKI
FLNB
SKI
FLNB
SKI
FLNB
SKI
FLNB
SKI
FLNB
SKI
FLNB

CD86
TRIB2
CD86
TRIB2
CD86
TRIB2
CD86
TRIB2
CD86
TRIB2
CD86
TRIB2
CD86
TRIB2
CD86
TRIB2

P2RX1
ATF4
P2RX1
ATF4
P2RX1
ATF4
P2RX1
ATF4
P2RX1
ATF4
P2RX1
ATF4
P2RX1
ATF4
P2RX1
ATF4

18S
GZMK
18S
GZMK
18S
GZMK
18S
GZMK
18S
GZMK
18S
GZMK
18S
GZMK
18S
GZMK

SEPT10
CCL5
SEPT10
CCL5
SEPT10
CCL5
SEPT10
CCL5
SEPT10
CCL5
SEPT10
CCL5
SEPT10
CCL5
SEPT10
CCL5

ZBTB20
BLNK
ZBTB20
BLNK
ZBTB20
BLNK
ZBTB20
BLNK
ZBTB20
BLNK
ZBTB20
BLNK
ZBTB20
BLNK
ZBTB20
BLNK

ZAP70
BANK1
ATRX;LOC728849
GAPDH
ZAP70
BANK1
ATRX;LOC728849
GAPDH
ZAP70
BANK1
ATRX;LOC728849
GAPDH
ZAP70
BANK1
ATRX;LOC728849
GAPDH
ZAP70
BANK1
ATRX;LOC728849
GAPDH
ZAP70
BANK1
ATRX;LOC728849
GAPDH
ZAP70
BANK1
ATRX;LOC728849
GAPDH
ZAP70
BANK1
ATRX;LOC728849
GAPDH

TNFRSF8
PGK1
TNFRSF8
PGK1
TNFRSF8
PGK1
TNFRSF8
PGK1
TNFRSF8
PGK1
TNFRSF8
PGK1
TNFRSF8
PGK1
TNFRSF8
PGK1

WSB2
ECE1
WSB2
ECE1
WSB2
ECE1
WSB2
ECE1
WSB2
ECE1
WSB2
ECE1
WSB2
ECE1
WSB2
ECE1

LPL
GUSB
LPL
GUSB
LPL
GUSB
LPL
GUSB
LPL
GUSB
LPL
GUSB
LPL
GUSB
LPL
GUSB

COBLL1
PRAME
COBLL1
PRAME
COBLL1
PRAME
COBLL1
PRAME
COBLL1
PRAME
COBLL1
PRAME
COBLL1
PRAME
COBLL1
PRAME

ANXA2
GLI1
ANXA2
GLI1
ANXA2
GLI1
ANXA2
GLI1
ANXA2
GLI1
ANXA2
GLI1
ANXA2
GLI1
ANXA2
GLI1

FGFR1
AURKA
FGFR1
AURKA
FGFR1
AURKA
FGFR1
AURKA
FGFR1
AURKA
FGFR1
AURKA
FGFR1
AURKA
FGFR1
AURKA

GFI1
SIRT1
GFI1
SIRT1
GFI1
SIRT1
GFI1
SIRT1
GFI1
SIRT1
GFI1
SIRT1
GFI1
SIRT1
GFI1
SIRT1

CRY1
CHEK1
CRY1
CHEK1
CRY1
CHEK1
CRY1
CHEK1
CRY1
CHEK1
CRY1
CHEK1
CRY1
CHEK1
CRY1
CHEK1

LDOC1
FOXO1
LDOC1
FOXO1
LDOC1
FOXO1
LDOC1
FOXO1
LDOC1
FOXO1
LDOC1
FOXO1
LDOC1
FOXO1
LDOC1
FOXO1

Figure 16. Topographic view of the QRT-PCR assays for the genes printed on microfluidics card. The card includes 8 ports for
loading 8 samples (on the left vertical side). Each sample is evaluated by QRT-PCR assay for 48 genes, extended to two rows. The
genes 18S rRNA, GAPD, PGK1, GUSB, and ECE-1 served as endogenous controls.
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Gene
LDOC1
GFI1
FOXO1
TRIB2
AURKA
FGL2
NUDC
GLI1
AICDA
18S
LPL
ATRX
NT5C2
LASS6
EGR3
SIRT1
P2RX1
CCL5
SLAMF1
ATF4
GAPDH
OAS3
SEPT10
CD14
PGK1
RIOK2
SKI
ZAP70
TNFRSF8
CD86
PRAME
NRIP1
MLXIP
CRY1
BCL7A
GUSB
CHEK1
ANXA2
FLNB
COBLL1
WSB2
BANK1
GZMK
TPST2
ECE1
ZBTB20
FGFR1

Fold Change
6.14
2.79
1.21
1.34
1.11
0.28
0.86
0.72
0.18
0.77
1.07
1.98
0.66
1.30
1.75
0.92
1.90
0.90
0.15
1.08
1.14
1.33
0.94
1.26
1.10
0.82
0.85
1.07
2.94
2.44
1.06
1.05
0.81
1.05
0.91
1.02
1.05
0.98
1.02
0.93
1.02
0.98
1.18
0.99
1.01
1.01
1.00
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T stats
24.75
8.37
4.62
2.42
2.32
-1.88
-1.85
-1.78
-1.73
-1.68
1.64
1.57
-1.50
1.46
1.37
-1.33
1.32
-1.31
-1.31
1.19
1.11
1.03
-0.98
0.96
0.93
-0.93
-0.89
0.75
0.70
0.61
0.59
0.55
-0.54
0.45
-0.44
0.44
0.40
-0.36
0.33
-0.32
0.26
-0.25
0.21
-0.15
0.14
0.10
0.08

P value
0.00002
0.00111
0.00986
0.07292
0.08075
0.13397
0.13782
0.14972
0.15958
0.16744
0.17612
0.19128
0.20780
0.21713
0.24332
0.25569
0.25755
0.25888
0.26063
0.30134
0.33028
0.36025
0.38411
0.39318
0.40309
0.40489
0.42531
0.49723
0.52318
0.57745
0.58430
0.61246
0.62055
0.67826
0.67990
0.68507
0.71118
0.73460
0.75607
0.76576
0.80527
0.81418
0.84117
0.88745
0.89667
0.92558
0.93820

Table 5. The expression fold change values and significance of the genes in HeLa
samples that are run on microfluidics cards. The T statistics show the direction of the
expression change relative to LDOC1. A positive value indicates an increase in gene
expression; a negative value indicates a decrease in gene expression. Genes that are
concordant show the same direction of change in CLL and HeLa samples. Internal
controls are 18S rRNA, GAPD, PGK1, GUSB, and ECE-1 genes.

Next, the CLL data that were previously collected using this card from 76 patients
were grouped into LDOC1-high (27 patients) and LDOC1-low (49 patients) categories,
and a two-group t-test was applied to determine the genes that were concordantly
differentially expressed. We identified 30 differentially-expressed genes between the
LDOC1-high and LDOC1-low CLL groups. When we compared this list of differentially
expressed genes with the list obtained from our MF-QRT-PCR analysis of the HeLa
samples, only LDOC1 and GFI1 showed concordant differential expression.

6.3

Summary

In this section, we used two approaches to identify and subsequently validate
genes with concordant LDOC1 expression in transfected HeLa cells and CLL samples.
First, we compared the gene expression profiling data obtained using Affymetrix
microarrays from the current HeLa experiment and a previously-performed CLL study in
our laboratory (34). This approach identified 51 genes in common. We attempted to
validate, by QRT-PCR assay, 6 genes from this list whose function suggested that they
might contribute to oncogenesis: NRIP1, DNAJA1, UBE2N, ITGAL, MAPKAPK2, and
CLCN4.

However, we were unable to validate any of these genes as differentially
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expressed in HeLa cells that are transfected with LDOC1 siRNAs or non-targeting
siRNAs. Second, we compared the gene expression data for 43 candidate biomarkers
of prognosis obtained by the MF-QRT-PCR assay from 76 CLL samples with the
transfected HeLa cells. This analysis identified GFI1 (Growth Factor-Independence 1) as
concordantly differentially expressed in both transfected HeLa cells and CLL samples.
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CHAPTER 7.

DISCUSSION

We previously identified LDOC1 as one of the most significantly differentially
expressed genes in untreated CLL patients (22). This dissertation extends that study
and addresses two major questions with respect to LDOC1: 1) Does LDOC1 mRNA
expression correlate with other clinical parameters of prognosis and patient outcome,
thus serve as a novel biomarker of survival in untreated CLL patients?, and 2) How
does LDOC1 mRNA upregulation in unmutated CLL contribute to disease pathogenesis?

To address the first question, we have expanded our knowledge of LDOC1
mRNA expression in neoplastic and benign B cells (26). First, we have confirmed that
LDOC1 mRNA is dramatically down-regulated in mutated CLL cases compared with
unmutated cases in a larger patient cohort. It is possible that differences in LDOC1
mRNA expression may be related to the enhanced ability of unmutated CLL cases to
respond to proliferative stimuli and resist apoptosis compared to mutated CLL cases
(41). Second, we show that high levels LDOC1 mRNA expression correlate with
cytogenetic markers of poor prognosis and with high ZAP70 expression. Further, we
demonstrate that LDOC1 mRNA expression is an excellent predictor of overall survival
in previously-untreated CLL patients. Third, although the sample size is small, we find
that LDOC1 mRNA expression is associated with unmutated IGHV somatic mutation
status in other primary small B-cell lymphomas. Finally, we show that LDOC1 mRNA is
expressed in normal peripheral blood B cells, and that its expression is higher in the
naïve B cell than in the memory B cell fraction. A recent study that evaluated the gene
expression profiles of human cord blood subpopulations identified LDOC1 mRNA as
upregulated in the CD34+/CD133+ subpopulation, which contains hematopoietic stem
cells and progenitor cells, compared to the more mature CD34 /CD133 subpopulation
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(42). During the course of our study, we also discovered a novel splice variant, LDOC1S
that is co-expressed with LDOC1 mRNA in normal B cells, CLL and primary lymphoma
cells that we examined. These findings suggest that during the course of normal B-cell
development LDOC1 mRNA levels may vary with the maturational stage and state of
activation. An assessment of B cells obtained from different compartments and
subjected to a variety of different stimuli is required to address this question.

The presence or absence of somatic mutations in the IGHV genes separates
CLL patients into two prognostic subsets (4, 43). Patients with unmutated IGHV genes
have a median survival of 8 years compared to 25 years in patients with mutated IGHV
genes. Gene expression profiling studies using microarrays demonstrated that the
majority of unmutated CLL cases express ZAP70 mRNA (13). Subsequently, others
showed that expression of ZAP70 protein correlates with mutational status and clinical
outcome (14, 15). Recent studies suggest that ZAP70 protein expression may be a
better predictor of time to treatment than IGHV somatic mutation status (16, 17). In our
study, LDOC1 mRNA expression, IGHV somatic mutation status, and ZAP70 protein
expression all predicted time to treatment in univariate analyses. In multivariate
analyses, IGHV somatic mutation status performed marginally better than ZAP70 protein
expression, which performed marginally better than LDOC1 mRNA expression (data not
shown). However, our data indicate that expression of LDOC1 mRNA may predict
overall survival better than either IGHV somatic mutation status or ZAP70 protein
expression in previously untreated CLL patients.

Chromosomal abnormalities, predominantly gains and losses, are strong
independent predictors of prognosis in CLL. The most common abnormality is
del(13)(q14), followed by del(11)(q22.3), the site of the ATM gene, trisomy 12,
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del(6)(6q21-q23), and del(17)(p13), the site of the TP53 gene (7-9). In the clinical setting
these abnormalities are usually assessed using a panel of fluorescence in situ
hybridization (FISH) probes. As the sole abnormality, del(13)(q14) is associated with a
good prognosis. In contrast, del(6)(q21-q23), del(11)(q22.3), del(17)(p13), del(13)(q14)
with other abnormalities, and trisomy 12, are associated with more rapid disease
progression and inferior survival. The abnormalities del(17)(p13) and del(11)(q22.3) are
the most important independent cytogenetic markers of poor prognosis. Deletions in
17p13, the site of the TP53 gene, are associated with resistance to therapy with purine
analogs, such as fludarabine, and short survival (10-12). The IGHV somatic mutation
status is associated with cytogenetic abnormalities detected by FISH analysis (44-46).
For example, del(13)(q14) is found more often in mutated cases. Our results indicate
that LDOC1 mRNA expression was associated with cytogenetic markers of prognosis.
Cases that were LDOC1 mRNA negative were more likely to contain isolated
del(13)(q14), while LDOC1 mRNA positive cases were more likely to demonstrate
cytogenetic markers of poor prognosis. By SNP genotyping, no case showed loss of the
LDOC1 gene; three mutated cases showed a gain in the LDOC1 copy number, but were
negative for LDOC1 mRNA expression (data not shown). Further, we found no
mutations in LDOC1 mRNA in the subset of CLL cases that we subjected to sequence
analysis. Thus, the differences that we observed in levels of LDOC1 mRNA expression
in mutated compared to unmutated CLL cases appear to result neither from copy
number variation in the gene, nor mutations in the coding regions.

If LDOC1 functions as a transcription factor, as hypothesized, then small
alterations in its level of expression could profoundly affect other genes that it regulates,
and could promote or inhibit tumor formation, depending upon the context. We are the
first to report LDOC1S, a new splice variant of LDOC1. In cancer cells, altered
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expression of mRNA splice variants may result either from the generation of a new
mRNA variant or from a change in the tissue-specific ratio of normal mRNA isoforms.
An example of the former is Ikaros, a zinc finger DNA binding protein that is critical for
normal lymphocyte development network. Alternative splicing of Ikaros pre-mRNA yields
eight different isoforms, each with a different DNA binding capacity and differential
expression in normal and neoplastic lymphocytes (47). Alterations in the tissue-specific
ratio of normal mRNA isoforms may also be associated with tumorigenesis. For
example, Bcl-X, a member of the Bcl-2 family, undergoes alternative splicing to yield a
long mRNA, Bcl-XL, which has anti-apoptotic activity, and a short form, Bcl-XS, which
has pro-apoptotic activity. While Bcl-XL is primarily found in long-lived post-mitotic adult
tissues such as brain, Bcl-XS is expressed abundantly in cells with high turnover, such
as human lymphocytes. Loss of Bcl-XS expression is associated with shorter relapsefree and overall survival in patients with acute myeloid leukemia (AML) (48), and a high
ratio of Bcl-XL to Bcl-XS is associated with a poor prognosis in AML (49). Similarly, the
interferon regulatory factor-1 (IRF-1) is a transcriptional activator that may function as a
tumor suppressor gene. IRF-1 has five splice variants that lack various combinations of
exons 7, 8, and/or 9. Although the variants are expressed in both normal and malignant
cervical cells, they are found more abundantly in malignant cells. Most of the variants
have been shown to inhibit the transcriptional activity of the wild type IRF-1 (50).

If the LDOC1S mRNA splice variant were translated into protein, it would contain
the leucine zipper motif of the wild-type protein, but would lack the proline-rich region,
which contains an SH3-binding consensus sequence, and the acidic region in the Cterminus. Mizutani and co-workers (51) constructed LDOC1 deletion mutants, and
studied their localization and protein interactions following transfection into MDCK
(Madine-Darby canine kidney) cells. They found that full-length LDOC1 localized
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predominantly to the nucleus, whereas the N-terminal mutant protein (the leucine zipper
region) localized to both the nucleus and cytoplasm. They also identified WAVE3, a
predominantly cytoplasmic protein, as a binding partner of LDOC1. Co-expression of fulllength LDOC1 and WAVE3 proteins shifted the localization of LDOC1 from the nucleus
to the cytoplasm, and was associated with decreased apoptosis. They concluded,
therefore, that WAVE3 may inhibit the pro-apoptotic activity of LDOC1, either by
sequestering it in the cytoplasm or by shuttling it from the nucleus to cytoplasm.
Similarly, it is conceivable that LDOC1S binds to LDOC1 to form non-functional dimers
that inhibit the pro-apoptotic and anti-proliferative activities of LDOC1, possibly by
sequestering LDOC1 in the cytoplasm. Alternatively, within the nucleus LDOC1S could
form nonfunctional dimers with LDOC1; these could compete with functional LDOC1
dimers for DNA binding sites and inhibit its transcriptional regulatory activity. This
scenario would be similar to the inhibitory actions displayed by members of the Id protein
family, which contain helix-loop-helix dimerization domains but lack DNA binding
domains (52). Id proteins act in a dominant negative fashion and control critical events in
cell differentiation, proliferation and tumorigenesis. It is also possible that LDOC1S may
form non-functional heterodimers with other pro-apoptotic and/or anti-proliferative
proteins. Either mechanism might contribute to the aggressive behavior of some tumor
types that aberrantly express LDOC1 isoforms.

The relatively high expression of LDOC1 mRNA isoforms in unmutated CLL
cases compared to mutated cases, and their expression in a variety of tumor cell lines
suggest that LDOC1 may contribute to aggressive clinical behavior. Because we are a
tertiary care center, many of our patients received the diagnosis of CLL months to years
before seeking care at our hospital. Thus, we do not know the LDOC1 mRNA expression
status of their CLL cells at the time of initial diagnosis. We also do not know if LDOC1
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protein expression predicts overall survival in previously treated CLL patients. We have
been unable to identify a sensitive and specific commercially-available antibody for use
in either a Western blot or flow cytometry-based assay. However, QRT-PCR assays for
a variety of different mRNA transcripts, such as BCR/ABL1 fusion transcripts, are now
performed routinely in clinical molecular diagnostics laboratories (53). Thus, the lack of a
robust antibody does not preclude the use of LDOC1 mRNA expression as a clinically
relevant biomarker of prognosis. Whether LDOC1 mRNA expression is stable in cases
that have undergone clonal evolution over the disease course or following therapeutic
interventions, and if it is truly a better predictor of overall survival than either IGHV
somatic mutation status or ZAP70 protein expression can only be answered by a larger
longitudinal study.

After identifying LDOC1 as a novel biomarker to predict CLL prognosis, we next
asked whether the differential mRNA expression had biologic relevance to CLL
pathogenesis. Since very little is known about LDOC1, we performed global gene
expression profiling to gain an understanding of the biologic processes in which LDOC1
participates in general, and in B cell-related pathways, in particular. Gene expression
profiling of HeLa cells revealed 107 genes that are significantly differentially expressed
following LDOC1 protein knock-down. We further processed the 107 genes using
Ingenuity Pathways to identify potential interaction networks. We found that the
differentially expressed genes could be placed into a variety of pathways including
regulation of gene expression, cellular function and maintenance, cancer, cell cycle,
cellular growth and proliferation, cellular assembly and organization, cell death, and DNA
replication, recombination and repair. When these networks were inspected, we
identified several genes that participate in biologic processes in hematopoietic cells,
such as EBF (Early B cell Factor), which is essential for initiation of early B cell
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development from the lymphoid progenitor towards the pro-B cell stage (54, 55), and
HCK (Hematopoietic Cell Kinase), a protein tyrosine kinase that is expressed
predominantly in cells of lymphoid and myeloid lineage (56). However, the majority of
these 107 differentially expressed genes are of unknown function in hematopoiesis or
lymphomagenesis.

To identify and subsequently validate genes with concordant LDOC1 expression
in transfected HeLa cells and CLL samples, we used two approaches. First, we
compared the gene expression profiling data obtained using Affymetrix microarrays from
the current HeLa experiment and a previously-performed CLL study in our laboratory
(34). This approach identified 51 genes in common. We attempted to validate, by QRTPCR assay, 6 genes from this list whose function suggested that they might contribute to
oncogenesis: NRIP1, DNAJA1, UBE2N, ITGAL, MAPKAPK2, and CLCN4. However, we
were unable to validate any of these genes as differentially expressed in HeLa cells that
are transfected with LDOC1 siRNAs or non-targeting siRNAs. Second, we compared the
gene expression data for 43 candidate biomarkers of prognosis obtained by the MFQRT-PCR assay from 76 CLL samples with the transfected HeLa cells. This analysis
identified GFI1 as concordantly differentially expressed in both transfected HeLa cells
and CLL samples. We failed to detect GFI1 as differentially expressed in Affymetrix data
acquired from HeLa and CLL cells grouped into LDOC1-high and LDOC1-low
categories, possibly due to the smaller dynamic range of Affymetrix arrays compared to
the QRT-PCR assay (three orders of magnitude of expression compared to seven,
respectively) (20).

The gene Growth Factor-Independence 1 (GFI1) is a zinc finger transcription
factor that was first identified in T-cell lymphoma cell lines as the target of Moloney
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murine leukemia virus insertion, which resulted in enhanced cell growth. Upon activation
by viral insertion into its promoter, GFI1 conferred interleukin-2 (IL-2)-independent
proliferation to a IL-2-dependent T-cell lymphoma cell line (57). Subsequently, it was
shown that GFI1 is a transcription factor that contains a Snail/Gfi-1 (SNAG) domain, and
regulates gene expression by repressing transcription through its repressor domain
SNAG (58). The same study showed that GFI-1 overexpression inhibited cell death
induced by IL-2 withdrawal in IL-2 dependent T-cell lymphoma cell line. This escape
from cell death was strictly dependent on intact SNAG repression function (58). GFI1
inhibits cell death of IL-2-dependent T cell lymphoma cell-lines in IL-2-deficient media by
directly binding and repressing the promoter of Bax, a pro-apoptotic member of Bcl-2
family. The data also suggest that GFI1 represses the expression of another apoptosis
promoting protein, Bak (59).

Evidence for the oncogenic potential of GFI1 comes from in vivo studies using
transgenic mice. While a minority of mice transgenic for GFI1 alone developed T-cell
lymphoma, the vast majority of mice transgenic for GFI1 in combination with PIM-1 or LMYC developed T-cell lymphomas (60). In vitro studies support the hypothesis that
overexpression of GFI1 mediates lymphomagenesis. GFI1 has been shown to repress
cell cycle inhibitory genes, CDKN1A and CDKN2b, which encode the proteins p21Cip1
and p15INK4B, respectively (35, 61). However, the mechanism of this repression is
independent of DNA-binding by GFI1. GFI1 and c-Myc are recruited to the promoters of
these target genes by Miz-1, a transcription factor and interaction partner of c-Myc, to
form a complex. This protein complex allows GFI1 and c-Myc to cooperate to repress
transcription, without directly binding to the promoters of the target genes, and to
contribute to proliferation.
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GFI1 is expressed by hematopoietic stem cells (HSC), common lymphoid
progenitors, and granulocytic and monocytic progenitors (62). In vivo experiments using
GFI1 knock-out mice have shown that GFI1 maintains the self-renewal capacity of the
HSC by restricting their proliferative capacity (62, 63). Further, GFI1 also protects HSCs
from stress-induced apoptosis (64). In the hematopoietic system the gene expression
patterns of LDOC1 and GFI1 are similar: both are highly expressed in HSCs and
progenitor cells (42) and show higher expression in naïve peripheral blood B cells than
memory B cells according to our (26). Because both are highly expressed in HSCs, one
can speculate that LDOC1 may cooperate with GFI1 in maintaining HSC renewal; this
may have implications in maintenance of the leukemic stem cell as well.

Antigenic stimulation rapidly induces GFI1 expression in mature peripheral T
cells, which suggests that GFI1 participates in T cell activation (65). Constitutive GFI1
expression in Jurkat T lymphoma cells inhibits phorbol ester-induced G1 arrest by
blocking the negative cell cycle regulator, p21, and also inhibits activation-induced cell
death. It is not known if GFI1 expression is induced in benign or malignant B cells
following activation with antigen or other stimuli, such as IL-4, CpG oligonucleotides, or
IgM. Longo and co-workers have demonstrated that cells obtained from patients with an
aggressive disease course (usually unmutated CLL cases) respond to in vitro stimulation
by CpG oligonucleotides by proliferating. In contrast, CLL cells from patients with an
indolent disease course (usually mutated CLL cases) respond to stimulation by
undergoing apoptosis (41). Further, responsiveness to in vitro stimulation by CpG
oligonucleotides may be a better predictor of prognosis than IGHV somatic mutation
status (66). The findings that LDOC1 and GFI1 are expressed at significantly higher
levels in unmutated CLL cases (22), which are more responsive to antigenic stimuli, than
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in mutated cases, raise the possibility that both LDOC1 and GFI1 participate in signaling
pathways that promote proliferation in CLL cells and contribute to its pathogenesis.

A recent report demonstrates that the microRNA, miR155, is upregulated in
normal B cells that have been stimulated with IgM/CD40 ligand or CpG oligonucleotides
and in primary CLL cells, compared to unstimulated normal B cells. In human embryonic
kidney 293 cells miR155 has been shown to down-regulate LDOC1 mRNA expression
(67). Although we can find no published reports of GFI1 regulation by miR155, a
bioinformatic query of the TargetScanHuman database for microRNA binding sites
(www.targetscan.org, Release 5.1) for miR155 indicates that GFI1 has a putative binding
site for this microRNA in its 3’UTR. Thus, LDOC1 and GFI1 expression may be
coordinately regulated through miR155.

Our data raise the possibility that a potential interaction between GFI1 and
LDOC1 contributes to CLL pathophysiology, possibly by enhancing responsiveness to
antigenic stimulation. We have shown previously that high levels of mRNA expression of
both GFI1 (22) and LDOC1 (22, 26) are associated with unmutated IGHV somatic
mutation status, a marker of poor prognosis. In the current study, LDOC1 knock-down in
HeLa cells resulted in down-regulation of GFI1 mRNA. It also resulted in decreased
mRNA expression of two known GFI1 transcription targets, the pro-apoptotic gene BAX
(59) and the cell cycle repressor gene CDKN1A (35) (p values, 0.065 and 0.008,
respectively). Thus, it is possible that LDOC1 and GFI1 cooperate to inhibit apoptosis
and promote cell proliferation in aggressive CLL. Interestingly, a recent report has shown
that downregulation of Bax protein correlates with several parameters of poor prognosis
in CLL patients, including higher Binet stage, shorter lymphocyte doubling time, higher
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CD38 protein expression, and presence of chromosomal abnormalities in 11q and 17p
and/or a mutation of the ATM or TP53 genes (68).

It is conceivable that LDOC1 may directly regulate GFI1 gene expression by
binding to its promoter and activating its transcription. Alternatively, LDOC1 may interact
indirectly with GFI1 as part of the protein complex formed by Miz-1, GFI1 and c-Myc, as
described above, to regulate transcription of GFI1 target genes, such as BAX and
CDKN1A (35). Recent data suggest that c-Myc interacts with LDOC1 (69). Additional
studies, such as chromatin immunoprecipitation and reporter assays, could be
performed to determine if LDOC1 binds directly to the GFI1 promoter and controls its
transcription. Similar studies could also be performed to determine if LDOC1 interacts
with other proteins, for example, c-Myc, that regulate expression of GFI1 target genes
and contribute to malignant behavior.

It has been shown that following stimulation with CpG oligonucleotides in vitro,
CLL cells obtained from patients with an aggressive clinical course proliferate, whereas
CLL cells obtained from patients with an indolent course undergo apoptosis (41). The
same investigators also demonstrated that this proliferative response was generally
associated with unmutated IGHV status, and predicted shorter time-to-treatment,
progression free survival, and overall survival in a cohort of CLL patients. However,
mutated cases that proliferated under these conditions had a poorer prognosis than
mutated cases that underwent apoptosis (66). The finding that expression of both
LDOC1 and GFI1 are upregulated in unmutated CLL cases raises the possibility that
they interact to regulate the expression of the genes that enhance proliferation and/or
inhibit apoptosis in CLL cells. Since selection of antigens through the B cell receptor has
been implicated in the pathogenesis and progression of CLL (70-77), an in vitro study of
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LDOC1 and GFI1 expression following stimulation, as well as established downstream
pathways in CLL survival and proliferation, for example, Akt signaling (41), would be
highly illuminating.

In summary, we have shown that LDOC1 mRNA expression is an excellent
biomarker of overall survival in untreated CLL patients. Longitudinal studies in a larger
cohort of CLL patients are warranted to determine the value of LDOC1 mRNA
measurement as a clinical prognostic test. Our findings from gene expression profiling
studies suggest that GFI1 might be one of the key genes with which LDOC1 interacts to
contribute to CLL pathophysiology.
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APPENDIX

Supplemental Table 1. IGHV Somatic Mutation Status and Family, Expression of
LDOC1 mRNA and ZAP70 Protein, and Genomic Abnormalities of the CLL cases
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Abbreviations: M, mutated; U, unmutated; POS, positive; NEG, negative; NA, not
available.
* Total LDOC1 mRNA expression measured by MF-QRT-PCR assay
†
ZAP70 protein expression measured by immunohistochemistry or flow cytometry
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‡

Biallelic loss
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